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ABSTRACT 
In multiple Sclerosis (MS), a multifocal inflammatory demyelinating disease of the central 
nervous system (CNS), lesion distribution is highly variable between patients resulting in distinct 
patterns of disease progression and clinical deficits. The mechanisms that regulate immune cell 
migration to and subsequent lesion development in different areas of the CNS are not well 
understood.  
Experimental Autoimmune Encephalomyelits (EAE), a critical model in developing 
effective therapies in MS, can also be used to examine mechanisms driving lesion localization. In 
the adoptive transfer EAE model, transfer of myelin-specific CD4+ T cells into wild type (WT) 
mice results in an ascending paralysis due to inflammation predominantly in the spinal cord (SC) 
(conventional EAE), while transfer of these same T cells into mice lacking the interferon-g 
receptor (IFNgR) results in balance deficits due to inflammation predominantly in the brainstem 
(BS) (atypical EAE). The reciprocal transfer of IFNg KO myelin-specific T cells into WT mice 
results predominantly in atypical EAE. In addition to deficiencies in IFNg signaling, increased 
IL-17 signaling has also been shown to promote brain inflammation and atypical EAE 
pathogenesis. However, the mechanisms by which these cytokines promote distinct lesion 
localization are incompletely characterized.  
 IFNg and IL-17 play reciprocal roles in the recruitment of neutrophils to sites of 
inflammation. The absence of IFNg or increased IL-17 signaling can promote neutrophil 
infiltration in multiple infection and autoimmune models of disease. Some early studies 
examined neutrophil infiltration in EAE but none have examined their absolute requirement in 
atypical EAE.  
Using adoptive transfer models of EAE, we show that atypical EAE is driven by CXCR2-
mediated recruitment of neutrophils to the brainstem, whereas conventional EAE is driven by 
CCR2-mediated recruitment of monocytes to the spinal cord. We also find that IFNg signaling 
suppresses atypical EAE by directly inhibiting CXCL2-dependent neutrophil recruitment axis.  
IFNg directly inhibits CXCL2 production by monocyte and microglia in the BS during EAE. 
Additionally, IFNg suppresses neutrophil production of CXCL2 in response to CXCR2 binding 
by directly inhibiting expression of the CXCR2 receptor on neutrophils in the CNS.  Overall, 
 xii 
these studies identify a distinct CXCR2-dependent recruitment pathway in CNS autoimmunity 
that is not currently targeted by current disease modifying therapies.   
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CHAPTER 1 - INTRODUCTION 
 
 
Multiple Sclerosis (MS), an inflammatory demyelinating disease of the central nervous system 
(CNS), is one of the most common and costly autoimmune conditions in the world. There is a 
greater prevalence of MS in Western Europe and North America compared to the Middle East, 
Asia and Africa, however, the incidence of MS is increasing worldwide (1). The mean age of MS 
onset is 30 years of age with 70% of patients being diagnosed between the ages of 20 and 40 (2). 
The average cost of care for insured patients on current disease modifying therapies is 
approximately $27,000 dollars per year(3). Considering the early age of MS onset, increased 
prevalence of disease and longer overall life expectancy, these costs continue to escalate for 
patients as well as the healthcare system. Subsets of patients do not respond to the current 
disease modifying therapies, necessitating further study of MS in clinical studies and animal 
models.  
1a. MS: Heterogeneity in disease progression and pathology 
1a.i.  Complexity in MS diagnosis and disease progression  
Individuals with MS are generally classified into 3 subsets based on their clinical course. 
Relapsing-Remitting MS (RRMS), the most common form, is characterized by discrete attacks 
of neurological dysfunction that patients recover from, either partially or completely, early on.  
In the vast majority of RRMS patients the clinical course eventually transitions into a secondary 
progressive (SP) phase, during which relapses decrease in frequency and often disappear, only to 
be replaced by a slow indolent accumulation of disability.  Approximately 50% of RRMS 
patients develop Secondary Progressive MS within 10 years of diagnosis.  Primary Progressive 
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MS (PPMS), which occurs in 10-15% of cases, is characterized by a progressive decline without 
antecedent relapses. (Figure 1-1).  
Figure 1-1: Patterns of disability progression over time in PPMS, RRMS and SPMS. 
 
1a.ii.  Disease Pathogenesis 
 Clinical and neuropathological studies have implicated dysregulation of the immune 
system, particularly T cells and myeloid subsets, in the pathogenesis of MS. Hallmark features of 
MS plaques include perivascular infiltrates, primarily composed of T cells and 
monocyte/macrophages(4-6). Genome-wide association studies (GWAS) have shown that most 
susceptibility loci in MS involve immune system-associated genes. The strongest heritable risk 
factors have been found in major histocompatibility complex (MHC) loci (7, 8), and in MHC 
Class II genes in particular. Additionally, single nucleotide polymorphisms of  the IL-2 receptor  
(IL2RA) and IL-7 receptor alpha chains (IL7RA) have been associated with MS risk  (9).  
Collectively, the genetics of MS supports an autoimmune etiology and a role of  pathogenic 
CD4+ T cell responses.  
   
1a.iii.  Complexity in lesion location and type 
 Inflammation, demyelination, remyelination, neurodegeneration and glial scarring occur 
in the white and grey matter in the brain, spinal cord (SC) and optic nerves in all forms of 
MS(10, 11).  However, there is a great deal of heterogeneity in the location and microscopic 
appearance of lesions. The majority of patients have prominent periventricular, subcortical and 
brainstem (BS) white matter lesions. Some individuals have lesions predominantly in the SC and 
optic nerves(12, 13). An opticospinal form of MS is more prevalent in Asian populations(14). In 
addition to a skewed distribution of lesions, opticospinal MS differs from the conventional form 
MS (that is common in the Western Hemisphere) due to a greater prominence of neutrophils in 
Di
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y
Time
Primary Progressive MS (PPMS) Relapsing-Remitting MS (RRMS) Secondary Progressive MS (SPMS)
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parenchymal infiltrates. Cerebrospinal fluid (CSF) levels of the neutrophil recruitment-
promoting cytokine IL-17(15, 16) and the neutrophil chemoattractant IL-8 are higher in patients 
with opitcospinal compared to conventional MS(17). Another CNS autoimmune condition, 
neuromyelitis optica (NMO), is also characterized by a predominance of lesions in the optic 
nerves and spinal cord and neutrophil rich infiltrates(18). However, 70% of NMO patients test 
positive for the presence of anti-aquaporin 4 antibodies in the sera(19) whereas only a small 
percent of individuals with opticospinal(20) and conventional MS(21) are positive for the 
antibody. While NMO and opticospinal MS are thought to be distinct conditions there may have 
overlapping pathological pathways.  
Among patients with conventional MS there is also heterogeneity in the histopathological 
features of lesions.  An extensive neuropathological study compared 51 biopsy and 31 autopsy 
samples of actively demyelinating lesions and classified them into 4 distinct patterns(22). Pattern 
I, the most common form, was characterized by focal demyelination and perivascular cuffs 
populated with T cells and macrophages. Pattern II lesions resembled Pattern I lesions but were 
also notable for the presence of IgG and complement deposits. Unlike Patterns I and II, Pattern 
III lesions were not centered around veins or venules.  There was more diffuse demyelination, 
significant apoptosis of oligodendrocytes (23) and disproportionately decreased staining for 
myelin-associated glycoprotein (MAG). Pattern IV lesions were rare, found only in PPMS 
patients.  They differed from pattern III lesions in that oligodendrocyte loss did not appear to be 
due to apoptosis. While diffuse demyelination was present, the MAG protein was not 
preferentially depleted.  The complexity in the clinical manifestations and pathological findings 
in multiple sclerosis make it a difficult disease to study using only clinical assessments, patient 
samples and post-mortem pathology. Fortunately, an animal model, Experimental Autoimmune 
Encephalomyelitis (EAE), simulates many of the clinical and pathological features of MS and 
has provided insights into the mechanisms that drive autoimmune demyelination. 
1b. EAE 
1b.i.  Origins of the EAE model 
 The EAE model was largely discovered when Dr. Thomas M Rivers was studying rabies 
vaccinations at the Rockefeller Institute in the 1930s(24). At the time, rabies vaccines were 
produced by infecting animals with the rabies virus and pulling their CNS tissue during the end 
stages of the infection, inactivating the virus via ether-phenol incubation for use in rabies 
 4 
vaccination in humans(25). Dr. Rivers hypothesized that small amounts of active rabies virus 
present in such vaccines was responsible for neurological symptoms patients experienced 
following vaccination. When he tested this theory, animals that had been immunized with 
uninfected CNS tissue also developed neurological deficits. When CNS extracts were mixed 
with Complete Freund’s Adjuvant (CFA), invented in the 1940s, animals developed the 
neurological deficits at a higher frequency(26). Subsequent studies detailing the neuropathology 
of EAE revealed similar features to MS including primary damage to the white matter, focal 
lesions associated with blood vessels, and variability in lesion and symptom patterns(27). 
Subsequent whole CNS fractionation studies showed that immunization with fractions enriched 
for myelin basic protein were the most encephalitogenic(28).  
1b.ii.  EAE pathology induced by myelin-reactive T cells 
 To identify immunological mechanisms of EAE pathogenesis, investigators sought to 
identify an immune cell type isolated from myelin protein-immunized donors capable of 
transferring EAE to naive mice. Dr. Paterson at NYU showed that transferring whole lymph 
nodes from rats immunized with myelin peptide in CFA could induce EAE in naïve 
recipients(29). Subsequently, it was shown that incubating lymphoblasts from myelin 
protein/CFA-immunized rats with myelin protein and (MHC)-expressing, syngenic accessory 
cells improved the efficiency of adoptive transfer experiments, as fewer cells had to be 
transferred per animal(30). Subsequent studies demonstrated that CD4+ T cells isolated from the 
cultured cells were encephalitogenic.  
1b.iii. EAE model recapitulates variability in MS disease progression  
 Following the introduction of the EAE model, there was a rapid expansion into different 
mouse strains using different myelin peptides as the autoantigen. Initial studies found B10.PL, 
PL/J and SJL mouse strains developed EAE in response to immunization with MHC II-restricted 
Myelin Basic Protein (MBP) epitopes(31), but the clinical course varied between strains. B10.Pl 
and PL/J mice had acute monophasic encephalomyelitis while SJL mice had a clinical course 
that resembled RRMS(32, 33). A major breakthrough came when the peptide myelin 
oligodendrocyte glycoprotein residues 35-55 (MOG35-55) was found to be an encephalitogenic 
epitope in the C57BL/6 strain of mice(34). This discovery, coupled with the rapid expansion of 
genetic alterations made on the C57BL/6 background, facilitated more detailed mechanistic 
studies.  
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1b.iv. Modeling variable lesion localization in MS using the EAE model  
 EAE models can differ regarding predominant lesion location and clinical phenotype. In 
the majority of EAE models, the spinal cord is preferentially targeted, resulting in an ascending 
paralysis. These mice progress from a limp tail, to hind limb weakness, to paralysis of the hind 
limbs; in rare, severe cases there can be full paralysis or death(35). The clinical phenotype is 
referred to as conventional EAE (cEAE). In other models, for example C3H/Fej mice primed 
with the myelin peptide MOG97-114 generate Th17 effector cells that target the cerebellum, 
resulting in balance deficits. Conversely, C3H/Fej mice primed with the alternative peptide 
MOG35-55, generate Th1 effector cells that target the spinal cord, resulting in an ascending 
paralysis(36). Hence, there are intrinsic differences between inbred strains, as well as in T cells 
of different lineages and antigenic specificities, that may predispose towards either cEAE or 
aEAE.  
A prominent regulator of lesion location across multiple mouse backgrounds is the 
cytokine IFNg. In the absence of IFNg signaling, mice develop an axial rotary or atypical form of 
EAE (aEAE) that is characterized by a progressive loss of balance due to primary infiltration of 
the vestibular nucleus in the BS (37-41). In subsequent sections we will explore what is known 
about IFNg signaling in immune responses, MS and EAE and how it may regulate regional 
infiltration in CNS autoimmunity.  
1c. IFNg: pleiotropic cytokine in CNS autoimmunity 
1c.i. IFNg:  functionally distinct member of the Interferon family  
 Interferons (IFNs) were initially characterized as the secreted factors which interfere with 
viral replication(42, 43). Subsequent studies determined they comprise a diverse family of 
factors with distinct signaling pathways and roles in immune responses. The IFNs have been 
grouped into 2 distinct ligand types based on their receptor specificity. Type I IFNs, the most 
common of which are IFNa and IFNb, bind the heterodimeric receptor consisting of IFNAR1 
and IFNAR2. IFNg falls into its own category in the Type II IFN family, which binds the 
heterodimeric receptor consisting of IFNgR1 and IFNgR2(44). These receptors mediate distinct 
signaling pathways, Type I IFN receptors phosphorylate STAT 1 and 2, which heterodimerize 
and translocate to the nucleus and bind Interferon Response Elements (IREs) to mediate 
downstream signaling.  Type II IFN receptors predominantly signal through STAT1 homodimers 
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and bind Gamma Interferon Activation Sites (GAS) in promoter regions of target genes(45-47). 
Additionally, Type I Interferons are primarily produced by myeloid cells, particularly dendritic 
cells, and are critical effector molecules in direct anti-viral immunity. IFNg is produced by a 
variety of cell types, predominantly NK cells and T cells, and plays a much more prominent role 
in regulation of leukocyte trafficking, regulatory actions and defense against intracellular 
bacteria than direct anti-viral immunity(48, 49). While both Type I and Type II IFNs upregulate 
MHC molecule expression and can induce antibody class switching, IFNg plays a non-redundant 
role in Th1 cell differentiation and effector function(50, 51). Much like their functions within 
immune responses, Type I and Type II IFNs appear to have distinct effects on MS progression. 
IFNg is not an effective therapeutic in MS patients while Type I IFN administration is one of the 
more common treatments for RRMS. The role of IFNg in MS remains a complicated question 
with few answers and the mechanisms by which it influences CNS inflammation continue to be 
studied in the EAE model.  
1c.ii. IFNg role in controlling EAE severity 
 Multiple early studies showed IFNg signaling in EAE models could dampen CNS 
autoimmunity. Intrathecal administration of anti-IFNg antibody increased morbidity and 
mortality of EAE, while systemic administration of IFNg decreased disease severity, in mice(52). 
Additionally, in rats, intrathecal injection of IFNg decreased disease severity(53). Loss of IFNg 
signaling in IFNgRKO mice renders normally EAE resistant strains susceptible(54, 55) and 
induces more severe disease in mouse strains that were already susceptible to EAE(56). Studies 
with reciprocal bone marrow chimeric mice  showed that loss of IFNgR signaling in both the 
hematopoietic and non-hematopoietic compartments contribute to severity of disease(55). In 
addition to attenuating EAE severity, IFNg signaling also determines the primary site of 
inflammatory demyelination within the CNS and subsequent EAE clinical phenotype . 
1c.iii. IFNg role in suppressing aEAE phenotype 
A variety of model systems have shown that IFNg suppresses aEAE, but there is not a 
clear consensus on the mechanism by which this occurs. aEAE clinical symptoms were initially 
described as an axial rotation of the head and trunk due to primary infiltration of the BS and 
cerebellum(57). This is in contrast to the more common form, cEAE, which is characterized by 
an ascending paralysis due to primary infiltration of the SC. Multiple model systems have shown 
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greater incidence of aEAE, but none more consistently than those involving loss of IFNg 
signaling. In an EAE model where MBP-specific TCR-transgenic Rag KO mice spontaneously 
develop cEAE, researchers found that crossing the mice onto an IFNg KO background converted 
spontaneous cEAE to aEAE. Since T cell subsets are major producers of IFNg, subsequent 
studies of IFNg’s role on aEAE phenotype focused on the encephalitogenic CD4 T cells.  
Multiple theories about how IFNg suppresses aEAE emerged in the literature. In adoptive 
transfer experiments, hosts deficient in IFNgR signaling developed aEAE following adoptive 
transfer of MOG35-55-specific WT C57BL/6 CD4 Th1 polarized cells.  Transfer of the same cells 
into WT C57BL/6 mice resulted in cEAE. Similarly, transferring MOG35-55-specific IFNg KO 
CD4 T cells into WT C57BL/6 mice produced an aEAE phenotype.  Interestingly  MOG-specific 
IFNg KO CD4 cells can be regulated by MOG-specific WT CD4 T cells.  Hence in co-transfer 
experiments the incidence of aEAE declines in direct correlation with the ratio of WT to KO 
cells. Collectively, these data indicate that myelin-specific T cell production of, and host 
response to, IFNg determine lesion localization in EAE(39).  In another adoptive transfer 
paradigm, the specific myelin epitope used to immunize donor mice determines the Th lineage of 
encephalitogenic effector cells and the clinical phenotype of EAE that they induce .  Hence, 
C3Heb/Fej mice immunized with peptide MOG97-114, mount Th17 responses.  These Th17 cells 
induce aEAE in naïve recipients.  In contrast, immunization of C3Heb/Fej mice with the 
alternative peptide MOG35-55, triggers the generation of Th1 cells that induce cEAE.  If MOG94-
114-reactive CD4 T cells are polarized into Th1 cells via polarization with IL-12, they begin to 
induce  cEAE.  Conversely, polarization of MOG35-55-reactive CD4 T cells with IL-23 to drive 
Th17 differentiation makes them more likely to induce aEAE. (36).  
The observations that IFNg deficiency and IL-17 production are predisposing factors for 
the development of aEAE are not incompatible. IFNg can negatively regulate Th17 cell 
differentiation and suppress IL-17 production (58, 59).  Subsequent experiments with mice on 
the C57BL/6 background showed that encephalitogenic Th1-polarized IFNg KO CD4 T Cells, 
which induce aEAE when transferred to WT mice, induce cEAE when transferred to IL-17 
Receptor subunit A (IL-17RA) KO recipients(40).  These experiments demonstrate that IFNg 
signaling may directly suppress IL-17 production and subsequent signaling that is critical for 
aEAE pathogenesis. However, the absolute requirement of IL-17 signaling for aEAE 
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pathogenesis in the absence of functional IFNg signaling has not been demonstrated as IL-17RA 
KO cells can still produce IFNg and both transferred IFNg KO T cells and host cells can respond 
to IFNg. The absence of IFNg signaling may be required for aEAE, and IL-17 simply enhances 
the aEAE phenotype. Current experiments analyzing mechanisms by which IFNg affects lesion 
localization have focused on CD4 T cells and have not examined direct effects of IFNγ on 
myeloid cell recruitment and behavior subsequent to CD4 T cell infiltration of the CNS.  
 
1d. Neutrophils  
1d.i.  Neutrophil role in inflammation and autoimmunity 
 Neutrophils are some of the first responders at sites of injury and infection. They are 
often overlooked, as they enter tissue and are cleared early in an immune response. However, 
they comprise 20% of mouse and 80% of human blood leukocytes(60), are crucial mediators of 
anti-bacterial and anti-fungal immunity, and are potent cells in resolution of inflammation and 
promotion of wound repair (61, 62). Conversely, neutrophils also play critical roles in overactive 
immune responses, contributing to pulmonary inflammation in asthma(63) as well as joint 
damage in rheumatoid arthritis(64).  
 
1d.ii. Granulocyte colony stimulating factor (G-CSF) and CXCR2: major players in neutrophil 
mobilization and migration into inflamed tissue 
 Mobilization of neutrophils to the site of inflammation is a rapid process with a few 
critical drivers. During an infection or damage to tissue, G-CSF levels are rapidly upregulated in 
the serum(65), which promotes the proliferation and differentiation of neutrophil progenitor cells 
in the bone marrow(66). Part of the neutrophil differentiation process that promotes their release 
out of the bone marrow is the upregulation of the chemokine receptor CXCR2, which is 
mediated by G-CSF-dependent signaling(67). CXCR2 is, also, a critical mediator of neutrophil 
infiltration into inflamed tissue (68). The major ligands for CXCR2 in the mouse are CXCL1 and 
CXCL2 (69). Both ligands can bind the receptor and promote neutrophil chemotaxis as well as 
production of CXCL2(70). Multiple studies have identified tissue resident cells, such as 
endothelial cells and fibroblasts, as producers of CXCL1(70), while infiltrating immune cells 
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produce more CXCL2(70). The regulation of neutrophil recruitment factors is also relevant in the 
MS literature.    
 
1d.iii. Neutrophils in MS 
 Neutrophils are not often found in neuropathological studies of MS lesions. However, 
MS lesions in biopsy and autopsy samples tend to be well established. Neutrophils may be more 
conspicuous in early lesions and their short-lived presence in immune responses may have led to 
an underestimation of their importance. A role of neutrophils was inadvertently suggested when 
some MS patients, enrolled in experimental protocols of high-dose chemotherapy with peripheral 
blood stem cell rescue, experienced neurological worsening and new lesion formation while 
receiving G-CSF.  Administration of G-CSF was also associated with severe NMO relapses 
indicating that mobilization of neutrophils may lead to exacerbation of neuroinflammation in 
CNS autoimmunity(71-73). Another case of severe exacerbation of RRMS after G-CSF therapy 
was recently reported(74). After the discovery that G-CSF administration to MS patients was 
associated with severe MS and NMO relapses, it was shown that G-CSF transcript levels were 
elevated in MS patient lesion biopsies compared to healthy controls(75). Additionally, neutrophil 
chemoattractants were elevated in the CSF(17) and serum(76) of some MS patients. Circulating 
neutrophils from MS patients also show higher levels of activation including increased surface 
expression of chemokine receptors, increased oxidative burst and degranulation as well as lower 
levels of apoptosis following stimulation with GM-CSF(77).  
 While there is emerging evidence that neutrophils may contribute to MS pathology, 
current disease modifying treatments do not specifically target neutrophils. The most effective 
treatment in MS is a humanized anti-a4 intergrin antibody, natalizumab, which can block 
function of a4b1 and a4b7 integrin pairs and restrict peripheral blood mononuclear cell 
infiltration into tissue, however, neutrophil migration is not affected. Initial clinical trials showed 
that monthly injections of the antibody could reduce the risk of sustained disability progression 
by 42 percent in RRMS patients(78). Natalizumab is not effective in all RRMS patients, and 
SPMS and PPMS patients do not generally respond to natalizumab(79). It has recently been 
shown that patients that transitioned to SPMS had elevated levels of neutrophil chemoattractant 
CXCL1 and pro-survival factor G-CSF(80). Current disease modifying therapies were developed 
based on the assumption that MS is driven primarily by lymphocyte and monocyte/macrophage 
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populations that require a4 integrin for tissue infiltration. Emerging evidence indicates that these 
may not be the only cell types and recruitment pathways involved in CNS infiltration and MS 
pathogenesis.  
 
1d.iv. Role of Neutrophils in cEAE 
 Although the former discussion focused on the prominence of neutrophils in infiltrates of 
mice with aEAE, neutrophils also play a role in cEAE.  There is evidence in the literature that 
neutrophils may play a role in early lesion formation during cEAE. Administration of CXCR2+ 
Neutrophils to CXCR2 KO Balb/c mice following immunization restored EAE susceptibility 
(81). Administration of anti-Ly6G antibody prior to the onset of EAE in C57BL/6 WT mice 
blocked disease initiation but had no effect when given after onset of disease (82). Additionally, 
active immunization of G-CSFR KO C57BL/6 mice or administration of anti-CXCR2 antibody 
to WT mice decreased incidence of cEAE following active immunization(83). While neutrophils 
do appear to play a role in the induction of cEAE they are not sufficient to induce fulminant 
cEAE phenotype in C57BL/6 mice. Monocytes have been identified as the most common cells in 
SC lesions at the peak of cEAE(84). In addition it has been shown by us and other labs that loss 
off the monocyte chemokine receptor, CCR2, inhibits monocyte infiltration and attenuates cEAE 
severity(85-87). In conclusion, while neutrophils may contribute to the initial infiltration of cells 
into the SC they are not sufficient to induce fulminant cEAE.  
 
1d.v. IFNg promotes monocyte and T cell-dominant SC infiltration in cEAE 
IFNg is the dominant CD4 T cell derived cytokine in cEAE of C57BL/6 mice and may 
contribute to the predominance of monocytes and T cells at the peak of disease. In the CNS 
during cEAE, encephalitogenic CD4 T cells are predominantly IFNg producing.  This is true 
even when the donor cells are IL-23 polarized Th17 cells, since they transition into “ex-TH17” 
cells by the time they accumulate in the CNS(88). While induction of EAE in WT mice is 
associated with high levels expression of IFNg-inducible chemokines CXCL9 and CXCL10 in 
the CNS, those chemokines are largely absent in IFNgRKO mice(89). CXCL9 and CXCL10 bind 
the CXCR3 receptor that is expressed by both activated T cells and monocytes(90), potentially 
driving  their recruitment to the CNS . Additionally, it has been shown that IFNg promotes the 
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production of CCL2, an agonist for the CCR2 receptor on monocytes, by CNS tissue resident 
cells(91).  IFNg is also critical for the upregulation of VCAM-1 on the CNS endothelium(92). 
VCAM-1 is the predominant binding partner of integrin a4b1. a4b1 which is expressed at high 
levels by monocytes and T cells(93) and is thought to mediate infiltration of encephalitogenic T 
cells into CNS tissue(94). Circulating neutrophils are not predominant expressors of CXCR3 or 
CCR2 (95) and do not rely on a4 integrin for adhesion to endothelial cells in humans or mice 
(96-98). The majority of the IFNg-responsive pathways upregulated in the CNS during cEAE 
promote monocyte and T cell, but not neutrophil, infiltration.  
 
1d.vi. IFNg suppresses neutrophil infiltration in multiple models of inflammation 
In addition to actively promoting monocyte and T cell infiltration, there is evidence in 
multiple disease models that IFNg also suppresses neutrophil infiltration. Studies examining 
myelopoiesis during inflammation in mice showed that IFNg produced by activated CD4 T cells 
in the bone marrow promotes monopoiesis while suppressing granulopoiesis (99). In a 
pulmonary tuberculosis model, the loss of IFNgR expression in mice increased neutrophil 
infiltration into the lung(100). Additionally, it was shown that non-hematopoietic cell production 
of IFNg inhibited Th17 cell derived IL-17 production and neutrophil infiltration into the 
lung(101). Il-17 is known to promote neutrophil recruitment to areas of inflammation(15, 16). 
The evidence that IFNg inhibits neutrophil infiltration extends to the EAE model. Actively 
immunized  IFNgKO mice on the Balb/c background have enhanced neutrophil infiltration in 
both the SC and BS compared with their WT counterpaorts. Loss of IFNg signaling and 
increased IL17 signaling results in a heightened incidence of aEAE in multiple model 
systems(36, 40). (15, 16). The observation that increased pro-neutrophil recruiting cytokine IL-
17 and decreased neutrophil suppressing cytokine IFNg signaling promote aEAE may indicate 
that, downstream of Th1/Th17 differentiation, neutrophil recruitment to the brain is critical for 
aEAE pathogenesis. This question has not been explored in the literature.  
 
1e. Distinct migratory pathways to the CNS in aEAE and cEAE 
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1e.i. Patterns of CNS infiltration in cEAE and aEAE 
Neuropathological examination of cEAE and aEAE lesions show distinct patterns of 
infiltration. In the SC of WT hosts with cEAE, focal infiltration forms around venules and 
penetrates into white matter tissue. In the IFNgRKO hosts with aEAE, infiltrates accumulate in 
the meninges surrounding the lateral recess of the 4th ventricle of the BS and appear to extend  
directly into the BS parenchyma. The difference in lesion pattern may indicate that immune cells 
migrate to the CNS through distinct pathways to mediate disease.   
1e.ii. Blood Brain Barrier (BBB) 
The BBB is a highly restrictive barrier between the blood and CNS parenchyma, 
comprised of multiple layers which can restrict access of toxic compounds, pathogens and 
circulating immune cells(102). The endothelial cell barrier is strengthened by a combination of 
transmembrane and cytosolic accessory proteins that comprise the tight junctional complex.  The 
tight junction complex is bound to the endothelial cell actin cytoskeleton and forms an 
intercellular seal(103) Beyond the endothelium, a parenchymal basement membrane and 
astrocyte endfeet restrict immune cell migration from the perivascular space into CNS 
parenchyma(104). While its base function is to restrict entry into CNS tissue, inflammatory 
conditions can alter BBB function to promote immune cell infiltration.  
It has been shown in multiple models of CNS inflammation that factors critical for T cell 
and monocyte/macrophage infiltration are upregulated at the BBB in response to cytokines or 
other factors. In the EAE model upregulation of VCAM-1 on the BBB is critical for T cell 
infiltration into CNS tissue(94). BBB CNS endothelium is positive for CCL2 at pre-clinical and 
onset timepoints of cEAE(105). BBB endothelium and astrocyte expression of CCL2 was found 
to be critical for fulminant cEAE pathogenesis (106). While this is a major pathway of immune 
cell infiltration that fits well with immune cell subsets and histological patterns seen in cEAE 
there are alternative pathways of infiltration into the CNS. 
1e.iii. Blood CSF Barrier (BCSFB) 
 The BCSFB is the major restrictive barrier between the blood and CSF. CSF circulates 
throughout the ventricles and within the subarachnoid space over the brain and SC. It is a major 
protective buffer both to mechanical and chemical stresses and a source of growth factors to 
CNS tissue. CSF is produced and circulated by the choroid plexus epithelium, which is situated 
in the ventricles of the brain(107). The BCSFB is comprised of fenestrated endothelium and 
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choroid plexus epithelium located within the ventricles. The endothelium within the ventricles, 
unlike that in the BBB, does not play a major barrier function. The choroid plexus is the major 
barrier to chemical and cellular migration into CSF from the bloodstream mediated by 
functionally related, although separate, subsets of transmembrane and cytoplasmic proteins that 
comprise the tight junctional matrix(108).  
 The BCSFB also differs from the BBB in its role in immune cell surveillance during 
health and disease. While the CNS is often referred to as an “immune-privileged” site, there is 
constitutive immune monitoring at the level of the meninges to protect against infection and 
latent viral reactivation. The choroid plexus expression of P-selectin is thought to be a major 
pathway for memory CD4 and CD8 T cells to enter during surveillance(109) (110). The choroid 
plexus also plays a role in immune infiltration during CNS injury. In stroke models, the choroid 
plexus facilitates neutrophil infiltration via production of neutrophil chemoattractants CXCL1 
and CXCL2(111), which bind the CXCR2 receptor that is critical for neutrophil infiltration into 
inflamed tissue(112). The choroid plexus may be a major gateway that has, as of yet, been 
unexplored in aEAE.  
 
1f.  Summary of rationale and specific aims 
 MS is a complex CNS autoimmune demyelinating disease.  The mechanisms mediating 
damage in different areas of the CNS are not fully understood. T cells and antigen presenting 
cells, such as monocytes and macrophages, have been implicated as the primary drivers of 
destructive neuroinflammation based on GWAS and neuropathological studies. However, 
therapies that target monocyte, macrophage and T cell infiltration into CNS tissue are only 
effective in certain RRMS patients and not those with progressive forms of disease, indicating 
that other cell types and migratory pathways contribute to MS pathology.  
 Neutrophils are receiving increasing attention in MS pathogenesis. While they are not 
plentiful in most of the established MS lesions found in autopsy and biopsy specimens, they may 
play a transient and early role in lesion formation. Administration of neutrophil-mobilizing drugs 
has been associated with severe relapses in MS patients. Neutrophils isolated from peripheral 
blood of MS patients show a more activated phenotype compared to healthy controls. 
Additionally, neutrophil chemoattractants and survival factors were elevated in serum from 
patients with SPMS compared to RRMS. We previously reported that, in a longitudinal study of 
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untreated RRMS patients, plasma levels of the neutrophil attracting chemokine, CXCL5, rose in 
concert with new lesion formation(83). 
 The role of neutrophil in EAE is not completely understood. While they contribute to the 
initial infiltration in the SC in some models of cEAE, they appear to be dispensable for disease 
progression after clinical onset. In the C57BL/6 adoptive transfer cEAE model, CNS 
inflammation is dominated by IFNg signaling, which induces factors that promote CD4 T cell 
and monocyte infiltration into spinal cord tissue. In the absence of either IFNg production by 
encephalitogenic T cells or IFNγ responsiveness by host cells, mice predominantly develop 
aEAE. In the C57BL/6 IFNgKO T cell transfer model, it was shown that loss of IL-17 signaling 
in the host converted a normally aEAE phenotype to cEAE. Decreases in IFNg signaling and/or 
increases in IL-17 signaling have been shown to promote aEAE in other mouse backgrounds as 
well. A high IL-17 to IFNγ ratio in inflamed tissues is conducive to neutrophil infiltration in 
other models of inflammation.   
 In addition to variability in the types of cells recruited to the CNS, differences in lesion 
location may also be predicated on the pathways by which the inflammatory cells infiltrate the 
CNS. As mentioned above, intraparenchymal perivascular infiltrates are characteristic of cEAE. 
Endothelial cells and astroctyes at the blood brain barrier upregulate factors in response to IFNγ 
that facilitate monocyte and T cell infiltration into the CNS. These factors have been shown to be 
critical in cEAE induction. The pathway utilized by immune cells to infiltrate the brainstem 
during aEAE is less well characterized. Of note, the vestibulochoclear nucleus (VCO), which is 
one of the most heavily infiltrated and damaged areas in aEAE, is adjacent to the lateral recess of 
the 4th ventricle. The choroid plexus in the lateral recess of the 4th ventricle was shown to 
upregulate neutrophil chemoattractants in other models of CNS inflammation.  Based on these 
observations, we propose the following model of EAE pathogenesis: In WT hosts, IFNg 
producing myelin-specific CD4 T cells induce VCAM-1 and CCL2 expression in the 
endothelial cells and astrocytes of the BBB, promoting the recruitment of monocytes and 
additional CD4 T cells to the CNS where they primarily cause damage in the SC. In IFNgR 
KO recipients, BBB-dependent migratory pathways are not activated. Instead, myelin-
specific CD4 T cells migrate through the choroid plexus of the 4th ventricle and produce 
inflammatory factors, such as IL-6, TNFa, and IL-17, that activate the choroid plexus 
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epithelium and nearby microglia to produce neutrophil attracting chemokines, such as 
CXCL1 and CXCL2. This leads to the recruitment of neutrophils that initiate an 
inflammatory cascade leading to demyelination and axonopathy in the VCO and other 
regions in the posterior fossa. In WT mice IFNγ suppresses the production of the 
neutrophil attracting chemokines, thereby preventing brainstem infiltration by 
inflammatory cells. 
My thesis project builds upon this model by addressing the following aims: 
Aim 1: Chapter 2: Demonstrate that CXCR2-dependent accumulation of neutrophils is critical 
for aEAE pathogenesis. This finding identifies a specific cell type and recruitment pathway 
critical for aEAE pathogenesis. In addition, we find that aEAE does not require IL-17 signaling 
in the absence of loss of IFNg signaling.  
Aim 2: Chapter 3: Demonstrate that IFNg suppresses neutrophil infiltration into the BS by 
suppressing monocyte, microglial and neutrophil production of CXCL2.  In this study we 
identify that CXCL1 and CXCL2 are produced by distinct cell subsets. CXCL1 is produced by 
choroid plexus epithelium and astrocytes in EAE while CXCL2 is produced by CD45+CD11b+ 
cells in the BS parenchyma during aEAE. We also find that CXCL2 transcript production 
increases with aEAE disease severity and IFNg suppresses production of CXCL2 by all 
CD45+CD11b+ cell subsets and a positive feedback loop of CXCL2 production in neutrophils. 
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CHAPTER 2 - SITE-SPECIFIC CHEMOKINE EXPRESSION 
REGULATES CNS INFLAMMATION AND DETERMINES CLINICAL 
PHENOTYPE IN AUTOIMMUNE ENCEPHALOMYELITI2a. Abstract 
 
The adoptive transfer of myelin-reactive T cells into wildtype (WT)2 hosts results in spinal cord 
inflammation and ascending paralysis, referred to as conventional experimental autoutoimmune 
encephalitis (EAE)3, as opposed to brainstem inflammation and ataxia, which characterize disease 
in IFNgRKO hosts (atypical EAE).  Here we show that atypical EAE correlates with preferential 
upregulation of CXCL2 in the brainstem, and is driven by CXCR2 dependent recruitment of 
neutrophils.  In contrast, conventional EAE is associated with upregulation of CCL2 in the spinal 
cord, and is driven by recruitment of monocytes via a partially CCR2-dependent pathway. This 
study illustrates how regional differences in chemokine expression within a target organ shape the 
spatial pattern and composition of autoimmune infiltrates, leading to disparate clinical outcomes.   
 
2b. Introduction 
 
A defining feature of multiple sclerosis (MS) is the spatial dissemination of inflammatory 
demyelinating lesions within the CNS (1). In some patients, lesion burden is concentrated in the 
spinal cord with little involvement of the cerebrum (as in the opticospinal form of disease that is 
more common in Asia, or in a significant cohort of individuals with primary progressive MS) (2-
4).  In others, lesion burden is skewed supratentorially, with little to no involvement of the spinal 
cord (as in a significant cohort of individuals with relapsing remitting MS in the Western 
Hemisphere) (5, 6).  The factors that regulate leukocyte trafficking to, and accumulation in, 
particular regions of the CNS are poorly understood.   
EAE, widely used as an animal model of MS, classically manifests as an ascending 
paralysis that correlates with inflammatory demyelination of the lumbosacral spinal cord (7).  In 
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certain instances, an atypical form of EAE has been observed in which afflicted mice exhibit signs 
of imbalance/ vestibular dysfunction that correlate with lesion formation in the brainstem and/ or 
cerebellar white matter (8-13). This clinical phenotype occurs most consistently and prominently 
under circumstances where IFNg bioactivity is suppressed.   Hence, IFNg- and IFNg receptor 
(IFNgR)-deficient mice are significantly more likely to develop atypical EAE than their WT 
counterparts following active immunization (10). Adoptive transfer experiments have 
demonstrated that either deficient IFNg production by encephalitogenic donor T cells or impaired 
IFNg signaling into host cells is sufficient for the development of atypical EAE (12-14).   
In some experimental paradigms, a high incidence of atypical disease has been observed 
following the transfer of encephalitogenic T cell lines that contain a high ratio of Th17 to Th1 cells.  
In contrast, conventional disease is mediated by T cell lines that express a low Th17:Th1 ratio (11).  
A major function of IL-17, the signature Th17 cytokine, is to induce neutrophil 
mobilizing/activating factors, such as G-CSF, and chemokines that target granulocytes, such as 
CXCL1, CXCL2 and CXCL5 (15).  Conversely, IFNg skews myeloid cell differentiation in the 
bone marrow to favor monocytes over granulocytes during immune activation (16).  Therefore, it 
is not surprising that atypical disease tends to be characterized by neutrophil-rich white matter 
infiltrates, while monocytes are more prevalent in the infiltrates of mice with conventional disease 
(10, 13, 14).  However, a distinctive requirement for neutrophil mobilizing/ activating factors in 
atypical EAE versus monocyte mobilizing factors in conventional EAE has yet to be directly 
demonstrated. 
In the current paper we compared atypical and conventional EAE, induced in IFNgRKO 
and WT hosts, respectively, by transfer of the same population of myelin oligodendrocyte (MOG)6 
peptide-primed, IL-12 polarized CD4+ T cells.  We found that atypical EAE correlates with 
preferential upregulation of CXCL2 in the brainstem of IFNgRKO hosts, and is driven by CXCR2-
dependent recruitment of neutrophils to the white matter tracts surrounding the vestibulocochlear 
nucleus (VCO)7.  In WT mice, that have an intact IFNg signaling pathway, brainstem CXCL2 
expression is suppressed and spinal cord CCL2 is upregulated. Consequently, the autoimmune 
assault is redirected to the spinal cord and manifests as a monocyte-predominant infiltrate that is, 
in part, CCR2 dependent.   
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2c. Materials and Methods 
 
2c.i Mice  
8- to 14 week old CD45.1 congenic and WT C57BL/6 mice were obtained from NCI Fredrick or 
Jackson Laboratory. IFNgR knock-out (KO) (B6.129S7-Ifngr1tm1Agt/J)8 and IFNgKO 
(B6.129S7-Ifngtm1Ts/J) mice were obtained from Jackson Laboratory. Breeding pairs of IL-
17RKO originally obtained from from J. Kolls (LSU) and CCR2KO mice from B. Moore 
(University of Michigan) were bred in our facility.  Mice were housed in microisolator cages 
under specific pathogen-free conditions.  All animal protocols were approved by the University 
Committee on Use and Care of Animals. 
 
2c.ii. Antibodies and Reagents 
Rat antibody to myelin basic protein (MBP)9 (clone 12) was from Millipore. Mouse antibody to 
unphosphorylated filament –H (SMI)10 was from Covance. AlexaFluor594 goat-anti-mouse IgG 
and AlexaFluor488 goat-anti-rat IgG were from Life Technologies. The following antibodies 
were obtained from ebiosciences: FITC-anti-MHCII (M5/114.15.12), FITC-anti-B220 (RA3-
6132), PE-anti-CD45 (Ly5), PE-anti-CD8a (53-6.7), PE-anti-CD4 (Gk1.5), PE-anti-GM-CSF 
(MP1-22E9), PECy7-anti-CD11b (M1/70), and PECy7-anti-CD4 (RM4-5); PerCpCy5.5-anti-
Ly6C (HK1.4), PerCPCy5.5-anti-CD3e (145-2c11) and PerCPCy5.5-anti-IL17A (1787). The 
following antibodies were obtained from BD Biosciences:  allophycocyanin-anti-CD45.2 (104), 
FITC-anti-CD44 (IM7), allophycocyanin cy7-anti-Ly6G (IA8), allophycocyanin cy7-anti-
CD45.1 (A20), and allophycocyanin cy7-anti-IFNg (XMG1.2).  Rabbit polyclonal antiserum 
against the amino-terminal ligand binding domain on CXCR2 (MGEFKVDKFNIEDFFSG) was 
generated by Biosynthesis Inc. as previously described (17, 18).  Recombinant mouse (rm)11 
IFNg and rmIL-12 were from R&D Systems.   
 
2c.iii. Induction and scoring of EAE  
Donor mice were immunized subcutaneously with 100µg of peptide MOG35-55 (MEVGWYRSP-
FSRVVHLYRNGK, Biosynthesis) in CFA (Difco) across four sites over the flanks. Inguinal, 
axial and brachial lymph nodes were harvested 14 days post-immunization, pooled, 
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homogenized and passed through a 70µm strainer (BD Falcon). Cells were cultured with MOG35-
55 (50µg/mL) in the presence of rmIL-12 (6ng/mL), rmIFNg (2ng/mL) and anti-IL-4 mAb 
(hybridoma 11B11; 10µg/mL). After 96 h, CD4 T cells were isolated by column separation with 
CD4 (L3T4) magnetic microbeads, according to manufacturer’s instructions (Miltenyi). 5x106 
CD4 T cells (85-99% pure) were transferred i.p. into naïve hosts. Adoptive transfer recipients 
were monitored on a daily basis by an examiner who was blinded to experimental groups. Mice 
were scored for severity of conventional and atypical signs of EAE using established scales (14, 
19). Specifically, mice with conventional EAE were scored as follows: 0, no abnormality; 1, 
flaccid tail; 2, waddling gait/ difficulty righting from supine position; 3, overt hindlimb 
weakness; 4, hindlimb paralysis; 5, forelimb and hindlimb paralysis/moribund. Mice with 
atypical EAE were scored as follows: 0, no abnormality; 1, slight listing/difficulty righting; 2, 
obvious imbalance but able to ambulate; 3, severely impaired balance/ambulation; and 4, 
incapacitated due to inability to maintain upright posture/spinning. 
2c.iv.Histology 
After intracardiac perfusion of mice with 1xPBS and 4% paraformaldehyde (PFA)12, spinal cords 
and brainstems were removed.  The CNS tissues were then fixed in 4% PFA and cut into 50µm 
sections on a vibratome (Leica VT1200).  Free-floating immunofluorescent staining was 
performed with primary antibodies against MBP82-87 (1:500) and SMI32 (1:1000). Goat anti-
mouse IgG AlexaFluor 594 (1:400) and goat anti-rat IgG AlexaFluor 488 (1:1000) were used as 
secondary antibodies. Sections were incubated with DAPI (100ng/mL) prior to washing and 
mounting on slides (Prolong Gold anti-fade reagent, Life Technologies). Fluorescent images 
were acquired with Nikon Eclipse Ti, CoolSnapEZ camera and NIS Elements: Basic Research 
v3.10. Confocal images were acquired using a Nikon A-1 Confocal microscope (Nikon Plan 
Fluor 10x/0.30 or Nikon PlanApoVC 60x/1.40 oil) with diode-based laser system and NIS 
Elements software. 3D reconstruction images were generated with Bitplane software (Imaris) 
using confocal Z-stack images of equal thickness from each group. Appropriate processing, 
including image overlays and black level and brightness adjustments, were performed in Adobe 
Photoshop CS5.1 and applied equally to all samples and controls.  
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2c.v. CNS Inflammatory Cell Isolation 
CNS tissue was harvested and separated into four compartments: the spinal cord, brainstem, 
cerebellum and cerebrum. Each tissue was homogenized in 1mL PBS containing a protease 
inhibitor cocktail (Roche) and centrifuged at 800xg for 10 minutes. Supernatants were stored at -
80°C.  Tissue pellets were digested with collagenase A (1mg/mL) and DNAse I (1mg/mL) in 
HBSS containing calcium and magnesium.  Inflammatory cells were isolated over a 27/63% 
percoll gradient and counted with a Cellometer AutoT4 automated cell counter (Nexelcom).  
 
2c.vi. Flow Cytometry 
For surface staining, cells were suspended in PBS with 2%FCS containing Fc Block (50ng/mL) 
prior to incubation with fluorochrome-conjugated antibodies. For intracellular staining, cells 
were stimulated with PMA (50 ng/ml) and Ionomycin (2 µg/mL) and incubated with Brefeldin A 
(5 µg/mL) for 6-10 hours. Cells were then fixed in 4% PFA, permeabilized with 0.5% saponin 
and incubated with fluorochrome-conjugated anti-cytokine antibodies.  The stained cells were 
analyzed with a FACS Canto II flow cytometer using FACSDiva software (v6.1.3, Becton 
Dickenson).  Data was analyzed using FlowJo software (v9.3.2, Treestar).  
   
2c.vii. Multiplex Cytokine Analysis  
Cytokine levels in homogenate supernatants were measured via a luminex multiplex bead based 
assay (Millipore).  Data was collected on a Bio-Plex 200 system using the manufacturer’s 
protocols. The data shown indicates levels that fell within the linear portion of a corresponding 
standard curve. Bradford assays (Thermo Scientific) were performed on tissue homogenates in 
parallel for normalization to total protein. 
 
2c.viii. Statistical analysis  
Statistical analyses were performed using GraphPad Prism software. Two-way ANOVA with 
Sidak’s multiple comparisons test was used to compare disease scores over time. Leukocyte cell 
numbers and percentages, as well as chemokine and growth factor levels, were compared using 
the unpaired student’s t-test. A P value of <.05 (*) was considered significant.  P<0.01 is denoted 
as (**), P<0.001 as (***). 
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2d. Results 
2d.i. IFNgR deficiency in host cells increases the incidence of atypical EAE 
 
Following injection with IL-12 polarized MOG35-55-specific CD4+ T cells, 44 of 47 WT hosts 
(94%) and 38 of 48 IFNgRKO hosts (79%) developed clinical EAE.  The vast majority of 
afflicted WT mice had pure conventional disease (31 of 44, or 70%), characterized by an 
ascending paraparesis with no vestibular signs throughout the clinical course (Table 1, Figure2-
6).  Of the remainder, 4 (9%) had pure atypical disease (vestibular signs with no evidence of 
limb weakness) and 9 (21%) exhibited a mixed phenotype, marked by early signs of atypical 
disease (i.e. a head tilt) that invariably evolved into ascending paraparesis within 1-2 days. None 
of the WT mice that presented with conventional disease subsequently developed atypical signs. 
Conversely, the majority of IFNgRKO hosts underwent a pure atypical course (24 of 38, or 
62%), while 4 (11%) exhibited a pure conventional, and 10 (26%) a mixed, disease phenotype. 
 
Table 2-1: Conventional and Atypical disease incidence in WT and IFNgRKO recipients of 5x106 Th1-
polarized MOG35-55-reactive CD4 T cells 
 EAE Incidence Disease Phenotype Incidence  
WT 44/47 (93%) 
Pure Conventional 31/44 (71%) 
Pure Atypical 4/44 (9%) 
Mixed 9/44 (20%) 
IFNγRKO 38/48 (79%) 
Pure Conventional 4/38 (10%) 
Pure Atypical 24/38 (63%) 
Mixed 10/38 (27%) 
 
 
2d.ii. Inflammatory demyelination is prominent in the spinal cord of mice with conventional EAE 
and in the brainstem of mice with atypical EAE 
 
CNS tissues were collected from representative adoptive transfer recipients at peak disease and 
sections were examined by immunofluorescent staining. We consistently observed inflammatory 
infiltration, demyelination and axonopathy of white matter tracts in the spinal cords of WT mice 
with conventional EAE but not amongst IFNgRKO mice with atypical EAE (Figure 2-1, A and B, 
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left panels).  In contrast, IFNgRKO mice with atypical EAE displayed pathological changes in 
white matter surrounding the VCO of the brainstem (Figure 2-1A and 1B, right panels). 
Inflammation of the vestibulocochlear nerve root has also been highlighted in other models of 
atypical EAE (9, 12, 20). Consistent with these observations, significantly more CNS cells were 
isolated from the spinal cords of WT hosts at the peak of conventional EAE than from the spinal 
cords of IFNgRKO hosts at the peak of atypical EAE, while the reverse was true with respect to 
the numbers of inflammatory cells isolated from the brainstem (Figure 2-2A).  There were no 
significant differences between the two cohorts in the number of inflammatory cells isolated from 
either the cerebral hemispheres or the cerebella. 
 
Figure 2-1: The distribution of inflammatory demyelination in the CNS of mice with atypical and 
conventional EAE. (A) Representative spinal cord (left) and brainstem (right) sections from WT mice with 
conventional EAE and IFNgRKO mice with atypical EAE. Sections were stained for MBP (green) and DAPI (blue) 
to define foci of inflammatory demyelination (arrows). Scale bars are 500 µm in the spinal cord images and 100 µm 
in the brainstem images. (B) Confocal images of spinal cord and brainstem sections stained for MBP (green), SMI-
32 (red), and DAPI (blue). Demyelinated axons are SMI-32 positive, MBP negative (arrowheads). Scale bars, 30 
µm. 
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Spinal Cord Brainstem (VCO)
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A
WT IFNγRKO IFNγRKO
IFNγRKO IFNγRKO
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DAPI MBP  DAPI MBP  
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2d.iii. The severity of atypical EAE correlates with the number of brainstem neutrophils, while 
the severity of conventional EAE correlates with the number of spinal cord monocytes and donor 
T cells  
 
We performed a detailed analysis of the cellular composition of leukocytes infiltrating different 
CNS compartments of IFNgRKO mice that exclusively exhibited signs of atypical EAE (hereafter 
referred to as “pure atypical” disease) or of WT mice that exclusively exhibited signs of 
conventional EAE (hereafter referred to as “pure conventional” disease). Neutrophils comprised a 
higher percent of total live cells in all CNS compartments of mice with pure atypical EAE when 
compared to mice with pure conventional EAE (Figure 2-2B, left panel).  The absolute number of 
neutrophils was significantly increased in the brainstem, cerebrum and cerebellum of mice with 
pure atypical disease (Figure 2-2B, right panel).  In contrast, the percentages and absolute numbers 
of monocytes/ macrophages and donor T cells were significantly higher in the spinal cords of mice 
with conventional EAE (Figure 2-2C, 2D). The severity of pure atypical disease directly correlated 
with the number of neutrophils, but not monocytes/ macrophages, infiltrating the brainstem, while 
the severity of pure conventional EAE directly correlated with the number of monocytes/ 
macrophages and donor T cells, but not neutrophils, infiltrating the spinal cord (Figure 2-2F, 2G, 
and data not shown). Collectively, the above data suggest that pure atypical EAE is driven by 
accumulation of neutrophils in the brainstem, and pure conventional EAE is driven by 
accumulation of monocytes/ macrophages and CD4+ T cells in the spinal cord. 
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Figure 2-2. Neutrophils are prominent in the brainstem of IFNgRO mice with atypical EAE while monocytes 
and donor T cells are prominent in the spinal cord of WT mice with conventional EAE.   (A) The average 
number of total cells isolated from the spinal cord (SC), brainstem (BS), cerebellum (CBL), or cerebrum (CBM) of 
WT mice with pure conventional and IFNgRO mice with pure atypical EAE.  All animals had moderate to severe 
disease (clinical scores of 3-4) at the time of euthanasia. (B-E) Flow cytometry was performed to enumerate the 
percent and number of infiltrating neutrophils (CD11b+CD45+Ly6G+) (B), monocytes/ macrophages 
(CD11b+CD45hiLy6G-) (C), donor CD4+ T cells (CD3+CD4+CD45.1+)(D), and microglia (CD11b+CD45intLy6G-) 
(E).  (F and G) The absolute number of monocytes (MONO) and neutrophils (NEUT) per spinal cord (F) and 
brainstem (G) were compared between mice with mild (clinical scores 1-2) or severe (clinical scores 3-4) EAE. Data 
were pooled from at least 3 experiments with a total of 27 WT and 20 IFNgRKO mice.  Flow cytometry gating 
scheme is illustrated in Fig.2-7. *P<.05, **P<.01,***P<.001 
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2d.iv. CD4+ donor T cells traffic to the brainstem and upregulate CD25 and CD69 to a similar 
extent in WT and IFNgRKO hosts during the preclinical phase   
 
EAE lesion formation is initiated several days prior to clinical onset (21, 22).  The development 
of CNS infiltrates is contingent upon the passage of myelin epitope-specific effector T cells across 
the blood-brain-barrier (BBB)(13) or blood-cerebrospinal fluid barrier (BCSFB)(14) and their 
reactivation by local antigen presenting cells (23).  We questioned whether the distribution of EAE 
infiltrates in atypical versus conventional EAE reflects differences in trafficking patterns or 
reactivation of encephalitogenic T cells in the CNS during the preclinical phase.  To address that 
possibility, we adoptively transferred MOG35-55-primed, IL-12 polarized CD4+ T cells bearing a 
CD45.1 congenic marker into CD45.2+ WT and IFNgRKO hosts.  Representative mice in each 
group were euthanized at 1-2 days prior to expected clinical onset and at peak EAE, to analyze 
CNS infiltrating inflammatory cells by flow cytometry.  There was a trend toward a higher number 
of CD45.1+CD4+ donor T cells in the brainstem, as well as the spinal cord, of WT compared with 
IFNgRKO hosts at the preclinical time point (Figure 2-3A, 3B). A higher percent of CD45hiCD11b+ 
cells expressed MHC Class II in WT versus IFNgRKO CNS infiltrates (Figure 2-3C), 
demonstrating the presence of immunocompetent APCs in the brainstem of WT hosts.  There were 
no significant differences between the groups with respect to the number of CD11b+CD11c+ cells 
in either the brain or spinal cord (data not shown). The percent of CD25+CD69+ cells (indicative 
of recently activated cells) within the CD44+donor T cell population was also comparable between 
groups (Figure 2-3D).  Furthermore, we measured similar quantities of IL-2 protein in CNS tissue 
homogenates from WT and IFNgRKO hosts at clinical onset (data not shown). CD45.1+CD4+ 
donor T cells in the brainstem and spinal cord of WT hosts continued to outnumber those cells in 
IFNgRKO hosts at peak EAE (Figure 2-3A, 3B). Collectively, these results led us to conclude that 
the low incidence of atypical EAE in WT mice could not be attributed to impairment in the early 
migration of encephalitogenic T-cells to the brainstem, or in their reactivation once they had 
infiltrated the brainstem. However, increased accumulation of donor CD4+ T cells in the spinal 
cord could be, at least in part, responsible for the enhanced susceptibility of WT hosts to 
conventional EAE.  
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Figure 2-3. Enumeration of activated donor CD4+ T cells and antigen presenting cells in the CNS of WT 
versus IFNgRKO mice.  CNS-infiltrating cells were analyzed by flow cytometric analysis. (A and B) The average 
numbers of donor CD45.1+ CD4+ donor T cells (CD3+CD4+CD45.1+) the brainstem (A) or spinal cord (B) of WT 
and IFNgRKO hosts at preclinical and peak stages of EAE. (C and D) Percent  of CD45+CD11b+ that are MHCII+ 
(C) and donor CD44+CD4+ T cells that are CD25+CD69+  (D) in spinal cord and brainstem of WT and IFNgRKO at 
day 6 post-transfer (preclinical time point). The data are representative of three experiments with 3-6 mice per 
group. *P<.05,***P<.001 
 
2d.v. Neutrophil attracting chemokines are preferentially upregulated in the brainstem during 
pure atypical EAE, while monocyte attracting chemokines are preferentially upregulated in the 
spinal cord during pure conventional EAE 
 
We next focused on events downstream of effector T cell homing and reactivation. The 
development of clinical signs in EAE coincides with CNS infiltration by a secondary wave of 
circulating leukocytes, in large part composed of myeloid cells (24). To interrogate the factors that 
differentially recruit neutrophils to the brainstem of IFNgRKO hosts, and monocytes to the spinal 
cord of WT hosts, we collected CNS tissue homogenates from representative mice at clinical onset, 
and measured levels of candidate chemokines. CXCL2, CCL3, and CCL4 were preferentially 
expressed in brainstem homogenates of IFNgRKO hosts, while CCL2, CCL5, CXCL9 and 
CXCL10 were expressed at relatively high levels in spinal cord homogenates of WT hosts (Figure 
2-4).  Surprisingly, the neutrophil attracting chemokine CXCL1 was upregulated in the spinal cord 
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and brainstem of WT hosts.  The paucity of neutrophils in the CNS infiltrates of WT mice could 
be secondary to IFNg-mediated suppression of CXCR2 on neutrophils (25).   
 
Figure 2-4. Chemokine and growth factor expression in the spinal cord and brainstem of mice with pure 
conventional or pure atypical EAE.  Supernatants of spinal cord and brainstem homogenates obtained at clinical 
onset were subjected to Luminex based multiplex assays to measure levels of a panel of candidate chemokines.  
Data are pooled from 2 experiments with a total of 6 WT and 8 IFNgRKO mice per group. *P<.05, 
**P<.01,***P<.001 
 
2d.vi. IL-12 polarized T cells mediate atypical EAE in IFNgRKO hosts via an IL-17-independent 
pathway 
   
IL-17 is a potent inducer of CXCL2 (15).  In an independent model of EAE induced in the C3H 
strain, atypical EAE occurs only when Th17 effector cells outnumber Th1 effector cells and is 
suppressed by IL-17 blockade (11).   Although, in our model, donor T cells are polarized with IL-
12 and exhibit a classic Th1 profile prior to adoptive transfer (Figure 2-8), we entertained the 
possibility that they upregulate IL-17 themselves, or induce other cell types to produce IL-17, 
following transfer into IFNgRKO hosts. Therefore, we measured intracellular cytokine levels in 
CNS infiltrating leukocytes from symptomatic WT and IFNgRKO hosts. A significant percent of 
transferred CD45.1+ CD4+ donor T cells expressed IFNg (30-40%) and/ or GM-CSF (17-22%), 
irrespective of the tissue they had accumulated in, or of host genotype.  Conversely, we detected 
very few IL-17 expressing donor CD45.1+ CD4+ T cells or host CD45.2+CD4+ T cells in any of the 
tissues analyzed (< 5%). Consistent with these findings, IFNg protein was elevated in homogenates 
of brainstem and spinal cord tissues from WT and IFNgRKO hosts (620-1200 pg/mg), whereas 
IL-17 was undetectable or expressed at marginal levels (< 5 pg/mg protein).  Th2 cytokines (IL-4, 
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IL-5 and IL-13) were also undetectable or at the borderline of detection.  To more definitively 
assess the functional role of IL-17 in our experimental system, we transferred MOG35-55-primed, 
IL-12 polarized donor T cells into IL-17RKO, IFNgRKO or IFNgRKO x IL-17RKO mice.  The 
majority of IL-17R single knock-out mice (63%) developed pure conventional EAE without 
atypical features (Figure 2-5A).  IL-17R/IFNgR double knock-out mice exhibited a similar severity 
and incidence of atypical EAE to IFNgRKO mice (Figure 2-5A, and data not shown).  Taken 
together, these experiments demonstrate that, in our experimental paradigm, atypical EAE is IL-
17 independent. 
 
2d.vii. CXCR2 blockade abrogates atypical EAE, while CCR2 deficiency abrogates conventional 
EAE 
   
Based on the chemokine expression patterns shown in Figure 4, we hypothesized that CXCL2 
plays an instrumental role in the recruitment of neutrophils to the brainstem of IFNgRKO hosts.   
However, CCL3 and CCL4 were also induced in the brainstem of IFNgRKO adoptive transfer 
recipients (Figure 2-4), potentially providing a default chemokine pathway for leukocyte 
recruitment should CXCL2 be blocked.  Neutrophils are responsive to a broad array of 
chemoattractants, including formylated peptides and eicosanoids, that could also function in a 
redundant manner (26).  To directly assess the importance of ELR+ CXC chemokines in our 
experimental system, we treated WT and IFNgRKO hosts with anti-sera to CXCR2 (the receptor 
for CXCL1, CXCL2 and CXCL5) or control sera.  Preliminary studies showed that anti-CXCR2 
treatment selectively inhibited neutrophil infiltration of the CNS (Figure 2-9). CXCR2 blockade 
abrogated atypical EAE in IFNgRKO hosts, but did not alter the severity of conventional EAE in 
WT hosts (Figure 2-5B).  A small percentage of WT hosts treated with control antibody, but none 
of the WT hosts treated with anti-CXCR2, exhibited atypical signs (data not shown).   
 The onset of conventional EAE in WT mice is associated with spinal cord expression of 
the monocyte-attracting CC chemokine CCL2 (Figure 2-4). In parallel studies, we transferred 
MOG35-55-primed, IL-12 polarized WT or IFNgKO CD4+ T cells into syngeneic WT or CCR2KO 
hosts.  The severity of conventional EAE was significantly attenuated in CCR2KO compared with 
WT mice that received WT Th1 cells (Figure 2-5C).  Conversely, the low incidence of mice that 
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developed atypical features, and the severity of atypical signs, did not differ significantly between 
the groups.  Interestingly, CCR2KO hosts almost exclusively developed atypical EAE following 
transfer of IFNgKO Th1 donor cells, while WT hosts exhibited a mixture of conventional and 
atypical features (Figure 2-5D). 
 
Figure 2-5. The pathological role of signature cytokines and chemokines in IFNgRKO and WT adoptive 
transfer recipients. (A) MOG35-55 primed, IL-12 polarized CD4+ T cells were transferred into IL-17RKO, IFNgRKO 
or IFNgRKOxIL-17RKO mice. Data are pooled from two independent experiments with a total of 8 IL-17RKO, 8 
IFNgRKO and 11 IL-17RKOxIFNgRKO mice.  (B) WT and IFNgRKO mice were injected i.p. with aCXCR2 
antisera or control rabbit serum on days 0, 2, 4, 6, and 8 following the adoptive transfer of MOG-primed, Th1-
polarized CD4+ T cells. Conventional and atypical disease scores were averaged over 4 experiments with a total of 
20-23 mice per group. (C, D) WT and CCR2KO mice were injected with MOG35-55-primed, Th1-polarized CD4+ 
WT or IFNgKO T cells and rated for signs of conventional and atypical EAE.  WT T cell transfer data are pooled 
from two representative experiments with 15 WT and 7 CCR2KO recipients. IFNgKO T cell transfer data are from 
two representative experiments with 15 WT and 9 CCR2KO recipients. The experiment was repeated 4 times with 
similar results. *P<.05, **P<.01 
 
 
 
2e. Discussion 
 
Atypical EAE in IFNgRKO and conventional EAE in WT mice display diametrically different 
patterns in the spatial distribution of lesions across the neuroaxis.  Our data indicate that this is the 
consequence of distinct CNS region-specific chemokine production following the initial 
infiltration and reactivation of encephalitogenic T cells. In IFNgRKO mice, CXCL2 is 
preferentially upregulated in the brainstem.  Its cellular source remains to be identified.  Astrocytes 
and choroid epithelial cells are capable of producing ELR+ CXC chemokines (27-29), which is 
consistent with the recent observation that IFNg suppresses atypical EAE via modulation of a non-
A
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hematopoietic, radioresistant cell type (10). If brainstem astrocytes are the source of CXCL2, then 
they might comprise a distinct subset not found in the spinal cord. More definitive conclusions 
await experiments with IFNgR conditional knockout mice.  The factors that induce CXCL2 in the 
brainstem of IFNgRKO hosts are also unknown.  IL-17 was a logical candidate, since it stimulates 
the production of neutrophil attracting chemokines in a wide variety of cells (15) and has been 
implicated in alternative models of atypical EAE (11, 14).  However, our data demonstrate that 
atypical EAE induced by the transfer of MOG35-55-primed, Th1 polarized WT cells into IFNgRKO 
hosts is IL-17 independent (Figure 2-5).   Other candidates include IL-1, TNFa and GM-CSF, 
although the levels of those molecules were similar in brainstem and spinal cord homogenates 
from mice with atypical EAE, and were lower than their respective levels in homogenates from 
mice with conventional EAE (data not shown).  
In WT hosts, CCL2 is upregulated in both the spinal cord and brainstem, but only facilitates 
parenchymal infiltration of the spinal cord.   Donor T cells and monocytes appear to initially cross 
the BCSFB at the level of the fourth ventricle in WT hosts, but fail to penetrate deep into the 
brainstem distal to the choroid plexus (Figs 1 and 2).  This disparity may be the consequence of 
paradoxical effects of IFNg-modulated molecules that regulate leukocyte trafficking when 
expressed in different locations. For example, CXCL12 facilitates neuroinflammation when 
expressed on the luminal aspect of the cerebrovasculature, but curtails the migration of leukocytes 
beyond the perivascular space when translocated to the abluminal side (30). IFNg and IL-17 have 
opposing effects on the internalization of CXCL12 by brain microvessel endothelial cells. We are 
currently investigating the effects of IFNg, produced by encephalitogenic T cells, on the expression 
of adhesion molecules and chemokines by choroid plexus epithelial cells, glia and cerebrovascular/ 
meningovascular endothelial cells in vivo, and the repercussions for brainstem and spinal cord 
inflammation.    
Lesions are widely distributed throughout the neuroaxis in the majority of MS patients. 
However, across the spectrum of human demyelinating disease, there are subpopulations in 
which inflammatory demyelination is consistently focused in a particular region of the CNS, 
resulting in distinct clinical phenotypes (2, 3, 5, 6).  Analogous to atypical and conventional 
EAE, the pattern of inflammation in human disease tends to associate with particular CNS 
chemokine profiles and leukocyte subsets.  Although EAE does not perfectly simulate MS, the 
current data illustrates, in principle, how site-specific interactions between infiltrating immune 
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cells and CNS resident cells determine clinical and histopathological phenotypes of autoimmune 
demyelinating disease. Ultimately, the current line of research might lead to the identification of 
clinical and radiological features that correlate with CNS immune profiles, thereby facilitating 
clinical management. 
 
 
Figure 2-6. Conventional and atypical disease scores for WT and IFNγRKO recipients of Th1-polarized 
MOG-primed CD4 T cells. WT n=14, IFNγRKO n=29.  
0
1
2
3
4
C
on
ve
nt
io
na
l
di
se
as
e 
sc
or
e
0 5 10
Days post-transfer
WT
IFN RKO
0 5 10
Days post-transfer
A
ty
pi
ca
l
di
se
as
e 
sc
or
e
0
1
2
3
4 WT
IFN RKO
***
***
Supplemental Figure 1: Conventional and atypical disease scores for WT and IFNγRKO recipients of Th1-polarized MOG-primed CD4 T cells. WT n=14, IFNγRKO n=29. 
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Figure 2-7. Gating schemes for identifying myeloid and lymphoid cell subsets in CNS tissue. (a) Flow 
cytometry gating scheme for identifying donor CD4+ T cell populations as B220-CD3ε+CD4+CD45.1+ cells. (b) 
Myeloid cells (CD11b+) were separated into microglia (CD45intLy6G-), monocytes (CD45hiLy6G-), and 
neutrophils (CD45+Ly6G+). MHCII and Ly6C expression were used to confirm phenotypes of microglia, mono- 
cytes and neutrophils.  
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Supplemental Figure 2 : Gating schemes for identifying myeloid and lymphoid cell subsets in CNS tissue.      
(a) Flow cytometry gating scheme for identifying donor CD4+ T cell populations as B220-CD3ε+CD4+CD45.1+ 
cells. (b) Myeloid cells (CD11b+) were separated into microglia (CD45intLy6G-), monocytes (CD45hiLy6G-), and 
neutrophils (CD45+Ly6G+). MHCII and Ly6C expression w re used to confirm phenotypes of microglia, mono-
cytes and neutrophils.
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Figure 2-8. Cytokine production by Th1-polarized T cells following in vitro stimulation.  MOG35-55-primed, 
IL-12 polarized CD4 T cells were stimulated with PMA and ionomycin prior to intracellular staining and flow 
cytometric analysis. Histograms are gated on CD4+CD44+ T cells.  
 
Figure 2-9. Administration of CXCR2 antisera inhibits neutrophil accumulation in the spinal cord and 
brainstem in WT mice with EAE. Flow cytometric analysis of the spinal cord and brainstem isolated from score-
matched mice d9 post-CD4 T cell transfer to examine neutrophil infiltration.  
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Supplemental figure 3: MOG35-55-primed, IL-12 polarized CD4 T cells were stimulated with PMA and ionomycin prior 
to intracellular staining and flow cytometric analysis. Histograms are gated on CD4+CD44+ T cells.   
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CHAPTER 3 - IFNg MEDIATED REGULATION OF MYELOID DERIVED 
CXCL2 DETERMINES LESION LOCALIZATION DURING EAE 
 
3s. Abstract 
 
 The spatial distribution of lesions in the central nervous system (CNS) can vary widely 
among patients with multiple sclerosis (MS), or mice with experimental autoimmune 
encephalomyelitis (EAE). Cytokines produced by infiltrating leukocytes may control the sites 
where demyelinating lesions form. Hence, IFNg producing encephalitogenic Th1 cells induce 
conventional EAE (cEAE) in syngeneic wildtype hosts, characterized by ascending paralysis and 
monocyte predominant spinal cord inflammation.  Conversely, adoptive transfer of the same Th1 
effector cells into IFNg receptor (IFNgR) deficient mice results in atypical EAE (aEAE) 
characterized by gait imbalance and neutrophil-predominant brainstem inflammation.  CXCL2, a 
neutrophil attracting chemokine, is upregulated in the brainstem during aEAE; blockade of its 
cognate receptor, CXCR2, abrogates disease. Here we demonstrate that myeloid cells are the 
primary CNS source of CXCL2 during aEAE. We present evidence for an IFNg regulated 
CXCR2/ CXCL2 autocrine feedback loop in neutrophils that drives their progressive 
accumulation in brainstem white matter. In mice with cEAE, IFNg directly suppresses CXCR2 
expression by neutrophils, and CXCL2 expression by CNS infiltrating myeloid cells.  These data 
reveal a novel mechanism by which IFNg and CXCL2 interact to direct regional recruitment of 
inflammatory cells in the CNS, resulting in distinct clinical phenotypes. 
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3b. Introduction  
 
In multiple Sclerosis (MS), a multifocal inflammatory demyelinating disease of the 
central nervous system (CNS), the distribution of lesions can vary widely between patients, 
resulting in distinct clinical phenotypes. In some patients lesion burden is dispersed across CNS 
compartments, while in others it is skewed towards the spinal cord or cerebral white matter. (1, 
2) Little is known about the factors that determine which CNS regions are targeted in a given 
individual. Several models of experimental autoimmune encephalomyelitis (EAE) also 
demonstrate heterogeneity in the distribution of lesions. A common theme that has emerged is 
that IFNγ production by encephalitogenic T cells has a defining effect on lesion localization. 
Hence, adoptive transfer of Th1 polarized, encephalitogenic T cells derived from C57BL/6 
wildtype (WT) mice into IFNγ receptor deficient (IFNγRKO) hosts, or transfer of IFNγKO T 
cells into WT hosts, results in a high incidence of atypical EAE (aEAE) characterized by 
imbalance and brainstem or cerebellar inflammation(3, 4). We previously demonstrated that 
induction of aEAE in C57BL/6 IFNγRKO mice is dependent on CXCR2 mediated neutrophil 
infiltration of the pons, at the level of the vestibular cochlear nucleus(5). Conversely, transfer of 
WT T cells into WT hosts induces cEAE. with an ascending paralysis and infiltration of the 
thoracolumbar spinal cord. IFNγ promotes spinal cord inflammation by inducing the local 
expression of chemokines, such as CCL2 and CXCL10(6), and adhesion molecules, such as 
VCAM-1(7), which mediate the passage of T cells and monocytes across the BBB(8). Hence, 
cEAE is dependent on CCR2 and a4b1 integrin, the receptors for CCL2 and VCAM-1, 
respectively.   
In some EAE models the induction of cEAE versus aEAE correlates with the ratio of Th1 
over Th17 cells within the transferred donor T cell population(9). IL-17 is a strong inducer of G-
CSF and ELR+ CXC chemokines, factors that drive neutrophil mobilization and recruitment to 
sites of inflammation(10). IFNγ is known to suppress the differentiation of Th17 cells and 
production of IL-17. However, IL-17 may or may not play a critical role in aEAE pathogenesis 
depending on mouse strain and mode of disease induction. For example, IL-17 signaling is 
required for the induction of aEAE by IL-23 polarized T cells in C3H/Feb mice(9), but it is 
dispensible for the induction of aEAE by IL-12 polarized T cells in C57BL/6 IFNγKO mice(5). 
In the former model, astrocytes were identified as the major source of CXCL2 transcripts in the 
 52 
brain(11). In the current study we investigate the source of CXCL2 in the brainstem of C57BL/6 
IFNγKO mice with aEAE, the factors that promote its production, and the mechanism by which 
IFNγ regulates neutrophil infiltration and clinical aEAE.  
 
 
3c. Methods  
 
3c.i. Mice.   
8- to 14 week old CD45.1 congenic and WT C57BL/6 mice were obtained from NCI Fredrick. 
IFNgRKO mice were originally obtained from Jackson Laboratory and bred in the University of 
Michigan animal facilities. Mice were housed in microisolator cages under specific pathogen-
free conditions. All animal protocols were approved by the University Committee on Use and 
Care of Animals. 
 
3c.ii. Antibodies and Reagents.  
For flow cytometry the following antibodies were obtained from ebiosciences: PECy7-anti-
CD11b (M1/70), eFluor450-anti-CD45 (30-F11) and PerCpCy5.5-anti-Ly6C (HK1.4). 
Allophycocyanin cy7-anti-Ly6G (IA8) was from BD biosciences. For immunofluorescent 
histology Rabbit anti-GFAP (Gibco), rat anti-mouse CD45 (IBL-5/15, Millipore), goat anti-
mouse CXCL2, and anti-mouse CXCL1 (R&D Systems), rat anti-mouse Ly6G (IA8, BD 
Biosciences) and Ham anti-Mouse CD3e were used as primary antibodies. Secondary antibodies 
AlexaFluor594 donkey-anti-goat IgG, AlexaFluor488 goat-anti-rat IgG, goat anti-hamster and 
AlexaFluor647 goat-anti-rabbit IgG were obtained from life technologies. For in vitro cultures, 
recombinant mouse (rm) IFNg, rmIL-12, rmCXCL2, rmIL-1b and rmCXCL1 were from R&D 
Systems.   
 
3c.iii. Induction and scoring of EAE.  
Donor mice were immunized subcutaneously with 100µg MOG35-55 (MEVGWYRSP-
FSRVVHLYRNGK, Biosynthesis) in CFA (Difco) across four sites over the flanks. Inguinal, 
axial and brachial lymph nodes were harvested 14 days post-immunization, pooled, 
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homogenized and passed through a 70µm strainer (BD Falcon). Cells were cultured with MOG35-
55 (50µg/mL) in the presence of rmIL-12 (6ng/mL) and rmIFNg (2ng/mL). At 96 h, CD4 T cells 
were isolated by column separation with CD4 (L3T4) magnetic microbeads, according to 
manufacturer’s instructions (Miltenyi). 5x106 CD4 T cells (80-99% pure) were transferred i.p. 
into naïve hosts. Adoptive transfer recipients were monitored on a daily basis by an examiner 
who was blinded to experimental groups. Mice were scored for severity of conventional and 
atypical signs of EAE using established scales(4),(20).  
 
3c.iv. BMT.  
Bone marrow was isolated from femur and tibia of IFNgRKO or tdTomato mice and mixed at 
1:1 ratio. Following 2 6.5 Gy doses spaced out over 3 hours from an orthovoltage source to 
eliminate the recipient hematopoetic compartment. 5x106 cells from bone marrow mixture were 
injected into irradiated mice via the tail vein. Adoptive transfer experiments were performed at 
least 6 weeks post-transplant.  
 
3c.v. Histology.  
After perfusion with 1xPBS and 4% PFA CNS tissue was post-fixed in 4% PFA for 96h, 
decalcified in 0.5M EDTA for 96h and transferred into 30% sucrose for at least 48h prior to 
embedding in OCT and storage at -80°C. 10µm spinal cord and brain sections were were cut in 
cryostat at -20°C. For staining, in a humidified chamber, sections were incubated 1x PBS to 
remove OCT, then blocking solution (1x PBS 7.4pH, 10% Normal Donkey Serum, 0.5% Triton-
X100) for 1 hour prior to addition of primary antibodies overnight at 4°C. For secondary 
antibody staining, sections were incubated with AlexaFluor594 donkey-anti-Goat IgG, washed, 
then incubated with AlexaFluor488 goat-anti-rat IgG and AlexaFluor647 goat-anti-rabbit IgG. 
Subsequently, sections were incubated with DAPI (100ng/mL) prior to washing and mounting on 
slides (Anitfade Reagent, Southern Biotech). Confocal images were acquired using a Nikon A-1 
Confocal microscope (Nikon PlanApoVC 20x, 40x or 60x/1.40 oil) with diode-based laser 
system and NIS Elements software. Appropriate processing including image overlays, black 
level and brightness adjustments were performed in Adobe Photoshop CC2014  and applied 
equally to all samples and controls.  
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3c.vi. CNS Mononuclear Cell Isolation.  
CNS tissue was harvested and separated into the spinal cord and brainstem. Each tissue was 
homogenized in 1mL PBS containing a protease inhibitor cocktail (Roche) and centrifuged at 
800xg for 10 minutes. Supernatant from homogenization was frozen down for subsequent 
chemokine analysis, and tissue pellets were further homogenized in 27% percoll and spun at 
500xg for 20 minutes with slow brake. Cell pellets were counted on a Cellometer AutoT4 
automated cell counter with trypan blue exclusion used to assess viability (Nexelcom).  
 
3c.vii. Flow Cytometry.  
For surface staining, cells were resuspended in PBS+2% FCS containing Fc Block (50ng/mL) 
and Fixable Viability Dye efluor 506 (ebioscience) prior to incubation with fluorochrome-
conjugated antibodies. For intracellular staining, cells were incubated with Brefeldin A (10 
µg/mL) for 4 hours in the presence or absence of stimulation conditions. Cells were labeled with 
fluorochrome-conjugated cell surface antibodies as described above, fixed in 4% PFA, 
permeabilized with 0.5% saponin and incubated with fluorochrome-conjugated anti-cytokine or 
chemokine antibodies. Stained cells were run on a FACS Canto II flow cytometer (v6.1.3, 
Becton Dickenson) or sorted on the FACS Aria II using FACS Diva software. Data was analyzed 
using FlowJo software (v10.3.2, Treestar).  
 
3c.viii. BM and Neutrophil Isolation and Stimulation  
8-14 week old mice were sacrificed, femur and tibia were flushed and passed through cell strainer 
(70µm) with repeated washes. For monocyte stimulation, whole BM was plated in complete media 
(RPMI with 10% FCS, L-Glut (2mM, Gibco), Pen/Strep (1:100, Gibco), Soduim Pyruvate 
(12.5µM, Gibco) and 2-mercaptoethanol (55µm, Gibco)) in the presence of Brefeldin A 
(10µg/mL) in stimulation conditions containing LPS (1µg/mL) in the presence or absence of IFNg 
(2ng/mL) for 4 hours, then isolated for intracellular flow cytometric analysis of CXCL2. 
Neutrophils were purified by positive selection from bone marrow cell suspension using anti-Ly6G 
microbead kit (Miltenyi). Purified neutrophils were plated complete media in the presence or 
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absence of CXCL2 (20ng/mL), CXCL1 (20ng/mL), G-CSF (25ng/mL), IFNg (2ng/mL) or IL-1b 
(10ng/mL) and isolated following 1h in culture to examine CXCL2 mRNA expression.  
 
3c.ix. RNA isolation  
Cells from FACS or in vitro cell culture were spun down and resuspended in 1mL Trizol (Life 
Technologies). For RNA extraction, 200µL of chloroform was added to samples and mixed prior 
to centrifugation at 18000xg. Chloroform layer was moved to fresh tube with 500µL cold 
isopropanol, mixed and incubated for 15 minutes prior to purifying the RNA out using the RNeasy 
MiniKit (Qiagen) with on column DNase digestion per manufacturer’s instructions.    
 
3c.x. RT- and q-PCR 
RT-PCR was performed using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) per manufacturer’s instructions. For q-PCR, TaqMan Universal Master Mix and 
primer/probe sets for CXCL2, CXCR2 and GAPDH were purchased from Applied Biosystems 
and run on a MyIQ system using iQ5 software (BioRad) as described in manufacturer’s 
instructions.  
 
3c.xi. Statistics 
Statistical analyses were performed using GraphPad Prism software. Comparisons of cell number, 
transcript levels in transfers into WT and IFNgRKO mice were done using an unpaired Student t 
test. Comparisons of transcript levels in transfers into mixed bone marrow chimeras were or in 
vitro experiments were done using a paired Student t test. A p value < 0.05 (*) was considered 
significant, with p < 0.01 (**) and p < 0.001 (***). 
 
3d. Results  
 
3d.i. T cells and neutrophils infiltrate the meninges of mice with cEAE as well as aEAE, but only 
migrate into the BS Parenchyma in mice with aEAE  
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It has been suggested that the choroid plexus (located in the ventricles of the brain) is the initial 
portal of entry of encephalitogenic T cells into the CNS during cEAE(12), despite the fact that 
clinical deficits of those mice localize to the spinal cord. We questioned whether inflammatory 
cells traverse the choroid plexus and migrate into the meninges as early steps in the pathogenesis 
of both cEAE and aEAE, but only penetrate deeper into the brainstem parenchyma in mice with 
aEAE(9). Indeed, immunofluorescent histological studies revealed the presence of T cells 
(CD3e+ (green)) and neutrophils (Ly6G+(Red)) in the meninges, adjacent to the lateral recess of 
the 4th ventricle, at the onset of cEAE in WT recipients of MOG-specific Th1 cells (Figure 3-1 
left panels). However, inflammatory cells were not present in the underlying parenchymal white 
matter. In contrast, a dense neutrophil-rich infiltrate extended from the meninges into the BS 
parenchyma of IFNγRKO at the onset of aEAE (Figure 3-1 right panels). T cells were also 
detected, clustering around blood vessels, in the BS parenchymal tissue of the IFNγRKO hosts. 
This suggests that in cEAE, as opposed to aEAE, inflammatory cells are actively confined to the 
meninges, and/ or do not receive, or respond to, sufficient chemotactic stimuli to migrate into the 
adjacent white matter.   
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Figure 3-1: Neutrophils migrate into BS parenchyma at the onset of aEAE. Immunofluorescent histology for 
CD3e (green), Ly6G (red) and DAPI (blue) in WT mice at the onset of cEAE (left panels) and IFNgRKO mice at the 
onset of aEAE (right panels). 
 
3d.ii. IFNγ suppresses expression of CXCR2 by CNS-infiltrating neutrophils 
 
We previously demonstrated that the neutrophil attracting chemokine CXCL2 is upregulated in 
the brainstem of IFNγRKO, but not WT mice, following the adoptive transfer of 
encephalitogenic WT Th1 cells. Furthermore, blockade of CXCR2, the cognate receptor for 
CXCL2, abrogates brainstem inflammation and clinical aEAE in IFNγRKO hosts, but has no 
impact on cEAE in WT hosts. These observations led us to question whether IFNγ regulates 
CXCR2 expression by WT neutrophils as they infiltrate the CNS. CXCR2 is rapidly internalized 
following ligation by its cognate chemokines. Therefore, cell surface CXCR2 levels are not 
always a reliable indicator of CXCR2 production. Therefore, we measured CXCR2 transcripts in 
neutrophils harvested from mice with aEAE or cEAE by qRT-PCR. CXCR2 transcript levels 
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were significantly higher in neutrophils isolated from the brainstems and spinal cords of 
IFNγRKO hosts at aEAE onset compared with analogous neutrophils isolated from WT hosts at 
cEAE onset. There was no difference in CXCR2 expression by bone marrow neutrophils isolated 
from IFNγRKO versus WT hosts at the same time point (Figure 3-2A).   
We constructed mixed bone marrow chimeric mice in order to directly compare CXCR2 mRNA 
expression in IFNγ responsive versus unresponsive myeloid cells within the same CNS 
microenvironment during EAE. Lethally irradiated CD45.1 congenic mice were reconstituted 
with a mixture of bone marrow cells from WT and IFNγRKO donors. WT donor cells were 
distinguished by expression of a tdTomato reporter. The mixed BM chimeras were subsequently 
injected with MOG-specific Th1 cells to induce EAE, and CNS infiltrating cells, and bone 
marrow cells were harvested at clinical onset. Neutrophils derived from each donor pool were 
FACS sorted and subjected to RNA extraction and qRT-PCR analysis. CXCR2 mRNA levels 
were reproducibly higher in IFNγRKO neutrophils compared to paired WT neutrophils isolated 
from the CNS of the same mouse. In contrast, there were no differences in CXCL2 mRNA 
expression comparing WT versus IFNgRKO myeloid cells isolated from the bone marrow 
(Figure 3-2B). This suggests that IFNγ directly inhibits CXCR2 production by neutrophils in the 
CNS. 
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Figure 3-2: IFNg signaling directly regulates CXCR2 expression on neutrophils. (A) CD45+CD11b+Ly6G+ cells 
were FACS sorted from naïve BM as well as BM, SC and BS of mice at the onset of cEAE in WT and aEAE in 
IFNgRKO mice to examine CXCR2 transcript levels relative to GAPDH. WT n=10 IFNgRKO n=15 from two 
experiments. (B) CD45+CD11b+Ly6G+ cells were sorted into WT and IFNgRKO subsets from mixed BM chimeras 
at the onset of EAE out of the BM, SC, and BS and examined for CXCR2 transcript expression relative to GAPDH. 
n=13 from two experiments.  
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3d.iii.Myeloid cells are the primary source of CXCL2 in the BS of mice with aEAE  
 
The primary cellular source(s) of CXCL2 in the brainstem of C57BL/6 IFNγRKO injected with 
MOG-specific Th1 cells has not previously been identified. Using in situ hybridization, we 
detected CXCL2 transcripts within intraparenchymal brainstem infiltrates, but not in adjacent 
uninflamed white matter or in the meninges, at the peak of aEAE (Figure 3-3A and data not 
shown). Immunohistochemical studies indicated that the CXCL2 producers were exclusively 
CD45+, indicative of hematopoietic cells. The majority of the CD45+ cells that stained positively 
for CXCL2 had multilobulated nuclei, consistent with neutrophils. Although we were able to 
visualize GFAP+ astrocytes at the border of the infiltrates, none were CXCL2 positive (3-3B).  
The above data were corroborated by qRT-PCR analysis of cell subsets FACS sorted from the 
brainstem at the onset of aEAE.  Hence, CXCL2 transcript levels were highest in purified 
CD45hiCD11b+Ly6G+ neutrophils, followed by CD45hiCD11b+Ly6G- monocytes/ macrophages, 
and CD45intCD11b+Ly6G- microglia (Figure 3-4A). CXCL2 mRNA expression in brainstem-
infiltrating neutrophils, macrophages and microglia correlated with aEAE severity (Figure 3-4B). 
CXCL2 mRNA was barely detectable above background levels in CNS-infiltrating cells that 
were CD45+CD11b-, a cell surface phenotype consistent with lymphocytes. Similarly, 
intracellular staining and flow cytometric analysis demonstrated that neutrophils were the 
predominant producers of CXCL2 protein during aEAE (in terms of frequency of cells within the 
CXCL2+ population), followed by microglia and macrophages/ monocytes (Figure 3-4C). We 
did not detect CXCL2 protein in lymphoid cells or non-hematopoeitic CD45- cells. 
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Figure 3-3: CXCL2 is made by CD45+ cells in the BS parenchyma. CXCL1 is made by choroid plexus 
epithelium and astrocytes. (A) in situ hybridization of the BS at the onset of aEAE for CXCL2 mRNA (red) 
combined with DAPI (Blue) counter stain. (B) Immunofluorescent histology of BS infiltrates in aEAE staining for 
CD45 (green), GFAP (white), DAPI (blue) and CXCL2 (red).  
 
3d.iv. IFNg directly suppresses CXCL2 expression by neutrophils   
 
While the data in (Figure 3-2A) demonstrates that IFNγ could prevent brainstem inflammation 
and the development of aEAE via inhibition of CXCR2 expression on neutrophils, we questioned 
whether IFNγ also regulates CXCL2 production. Indeed, CXCL2 mRNA levels were 
reproducibly higher in IFNγRKO neutrophils and monocytes isolated from the brainstems of 
mixed bone marrow chimeric mice when compared with their paired WT counterparts (Figure 3-
4D). In contrast, there was no difference in CXCL2 mRNA expression comparing WT versus 
IFNgRKO myeloid cells isolated from the bone marrow of the chimeric mice (Figure 3-4D). This 
suggests that, similar to its effects on CXCR2 expression by neutrophils, IFNγ directly inhibits 
CXCL2 production by myeloid cells within the CNS. 
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Figure 3-4: CD45+CD11b+ cells are the primary source of CXCL2 in BS during aEAE. (A) neutrophils 
(CD45+CD11b+Ly6G+), monocyte/macrophage (CD45hiCD11b+Ly6G--), microglia (CD45loCD11b+Ly6G-) and non-
myeloid immune cells (CD45+CD11b-) were FAC sorted out of the BS of mice at the onset of aEAE and examine 
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for CXCL2 mRNA levels relative to GAPDH. IFNgRKO n=15 from two experiments. (B) Examination of cell 
number and CXCL2 mRNA expression per GAPDH of microglia, monocyte/macrophages and neutrophils at the 
onset of cEAE and aEAE. aEAE analysis was separated into mild onset (score=1) and severe onset (score³2). WT 
n=10 IFNgRKO n=15 from two experiments (C) BS infiltrates at the onset of aEAE were plated for 4 hours in the 
presence of brefeldin A and examined by flow cytometry to identify cellular subsets that were positive for CXCL2. 
n=6 from two experiments. (D) CXCL2 transcript per GAPDH was measured in neutrophils sorted out of mixed BM 
chimeras. n=13 from two experiments. 
 
3d.v. CXCL1 is expressed by non-hematopoietic CNS resident cells during EAE 
 
CXCL1 and CXCL2 are both ligands for CXCR2. In a previous study we made the paradoxical 
observation that, while CXCL2 is preferentially upregulated in the brainstem of IFNγRKO mice 
with aEAE, CXCL1 expression is elevated in the brainstem and spinal cord of WT hosts 
compared to IFNγKO hosts(5). It was unclear why CXCL1, produced in the CNS of WT hosts, 
did not compensate for low CXCL2 levels to stimulate local neutrophil infiltration. One 
possibility is that CXCL1 and CXCL2 are produced by different cell types at distinct locations 
within the brainstem. Indeed, immunohistochemical analyses showed that choroid plexus 
epithelial cells are a major source of CXCL1 during EAE in IFNγRKO mice (Figure 3-5B). This 
finding was corroborated by qRT-PCR, which revealed an upregulation of CXCL1 transcripts in 
the choroid plexus epithelium during aEAE (Figure 3-5A). We also detected CXCL1 in 
astrocytes and cerebrovascular endothelial cells in the spinal cords of WT hosts with cEAE 
(Figure 3-5B). We did not detect CXCL1 in infiltrating inflammatory cells, irrespective of the 
CNS compartment or genotype of the host.   
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Figure 3-5: CXCL1 transcript and protein is expressed by CNS-resident cells during EAE(A) qRT-PCR 
analysis of choroid plexus isolated from onset of cEAE, aEAE and IFNgRKO naïve mice (B) Immunofluorescent 
histology stain of choroid plexus and BS parenchyma in aEAE (600x) and SC in cEAE (400x) for CD45 (green), 
GFAP (white), DAPI (blue) and CXCL1 (red).  
 
3d.vi. IFNγ regulates a CXCL2 autocrine feedback loop in neutrophils  
IL-17 is a potent inducer of ELR+ CXC chemokines and has been shown to play a critical role in 
initiating neutrophil migration to the brainstem white matter in some models of aEAE. However, 
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in our model system aEAE is IL-17 independent. This raises the question of which factors drive 
CXCL2 production in the brainstem of IFNγRKO hosts. To address that issue, we assessed the 
ability of soluble factors that are upregulated in the brainstem during aEAE to stimulate CXCL2 
expression by bone marrow neutrophils in vitro. We found that CXCL2 mRNA was upregulated 
in neutrophils cultured with recombinant G-CSF, as well as with CXCL2 itself. Induction of 
CXCL2 mRNA expression by CXCL2 signaling was enhanced by the addition of IL-1b. IFNγ 
suppressed CXCL2 mRNA levels in neutrophils stimulated with either CXCL2 alone or 
combined with IL-1b, but had no effect on CXCL2 mRNA levels in neutrophils stimulated with 
G-CSF (Figure 3-6A and B). Ligation of TLRs on monocytes, macrophages and microglia is 
known to induce CXCL2 expression (13, 14). To examine whether CXCL2 expression in non-
granulocytic myeloid cells could regulated by IFNg, we cultured bone marrow derived 
monocytes with LPS in the presence or absence of IFNg. LPS stimulation induced CXCL2 
production in BM monocytes which was inhibited by IFNg (Figure 3-6C).      
 
 
 
 
 
 
 
 66 
 
Figure 3-6: IFNg directly suppresses distinct pathways of neutrophil and monocyte CXCL2 expression  (A-B) 
Neutrophils isolated from the BM were incubated in conditions for 1h to stimulate CXCL2 expression in the 
presence and absence of IFNg. n=8 from 3 experiments in figure A, n=3 in representative experiment shown in 
figure B of two replicates. (C) BM monocytes were stimulated in the presence of Brefeldin A with LPS in the 
presence and absence of IFNg for 4h. CXCL2 protein expression was analyzed by flow cytometry. N=3 in 
representative experiment of 3 replicates. 
  
3e. Discussion  
Based on our data we propose the following model by which an IFNγ/CXCL2 axis regulates the 
regional localization of inflammatory infiltrates during EAE. CXCL1 is released by choroid 
plexus epithelial cells in the early stages of both cEAE and aEAE, and promotes neutrophil 
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migration into the meninges. In IFNγRKO hosts the neutrophils are then stimulated to migrate 
further into the brainstem by a CXCL2 concentration gradient, possibly initiated by microglia 
and then amplified by neutrophils and monocytes as they accumulate in the brainstem white 
matter. CXCL2 production by neutrophils escalates during the progression of aEAE, driven by 
an autocrine positive feedback loop. In WT hosts, IFNγ, produced by myelin-specific T cells 
upon reactivation by APCs in the brainstem parenchyma, suppresses CXCL2 production by local 
myeloid cells. Consequently, production of CXCL1 by choroid plexus endothelium is not 
counterbalanced by a CXCL2 gradient from cells originating in the white matter parenchyma, 
effectively trapping neutrophils in the meningeal space. 
Our model is supported by the presence of similar regulatory mechanisms in other settings. 
Hence, in a model of type III hypersensitivity, it was shown that neutrophils respond to CXCL1 
and CXCL2 by upregulating CXCL2 transcript(15) and have the highest level of CXCL2 
transcript of all cells within inflamed tissue. Additionally IFNg signaling is known to regulate 
neutrophil expression of CXCR2(16), which may directly suppress neutrophil response to and 
production of CXCL2. 
Although CXCL2 is critical in both models of aEAE, Simmons et al. show that IL-17 and IFNg 
induce CXCL2 transcript expression in the BS and SC, respectively. In their model CXCL2 
transcript levels are highest in compartments where neutrophil numbers are greatest. If 
neutrophils are the predominant source of CXCL2 then the tissue compartment most heavily 
infiltrated by neutrophils would also have the highest levels of CXCL2 transcript. A LysM-Cre 
SOCS3fl/fl model of active immunization aEAE, also dependent upon neutrophil infiltration of the 
BS and cerebellum, found that neutrophils from SOCS3 deficient animals produced higher levels 
of CXCL2 in the BS and cerebellum during aEAE compared to WT controls(17, 18). While they 
found that other chemokines such as CXCL10 and CCL2 were also increased in their SOCS3 
deficient neutrophils, this is not entirely unsurprising as IFNg signaling remains intact in this 
model.     
 This CXCL2 dependent neutrophil recruitment represents a novel pathway of immune 
cell recruitment in CNS autoimmunity and indicates that multiple mechanisms exist by which 
immune cells can infiltrate the CNS and regulate lesion localization. Subsets of patients with 
distinct lesion localization patterns also had distinct cytokine and chemokine expression patterns 
in their serum and CSF(19). This damage to different areas of the CNS generates distinct clinical 
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deficits that may be indicative of recruitment pathways activated in individual patients, and what 
disease modifying therapies may be effective in their treatment. Analysis of chemokine levels in 
patient serum and CSF to lesion localization and patient response to disease modifying therapies 
could help to tailor treatment to individual patients.  
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CHAPTER 4-DISCUSSION AND FUTURE DIRECTIONS 
 
 
Previous work had outlined the importance of IFNg signaling in regulating lesion localization in 
EAE.  In adoptive transfer models, loss of IFNg production by transferred myelin-specific T cells 
or IFNg response in recipient mice altered disease focus from the spinal cord to the brainstem. In 
this work, we sought to identify critical points within the disease process where IFNg altered the 
focus of CNS inflammation and damage. In particular, we focused on how the host response to 
IFNg, following the transfer of a Th1-polarized myelin-specific T cell population, would alter 
each stage of disease in order to identify a potential divergence in the immune response that 
could elucidate what drives these distinct disease phenotypes.  
  
4a. The pattern of initial Encephalitogenic T cell infiltration is unaltered in the absence of 
IFNg signaling  
 
We and others found that aEAE in IFNgRKO adoptive transfer recipients (1,2) correlates with 
preferential infiltration of the brainstem, compared to WT mice with predominant cEAE due to 
preferential inflammation of the spinal cord (Table 2-1 and Figure 2-1). As the first stage of EAE 
is the recruitment of myelin-specific T cells, we questioned whether the infiltration patterns of 
encephalitogenic T cells at preclinical time points informed the localization of subsequent 
immune cell infiltration in WT and IFNgRKO mice. We found that there was not preferential 
accumulation of transferred T cells in the spinal cord of WT mice or the brainstem of IFNgRKO 
mice prior to disease onset (Figure 2-3A and B). Nor were there differences in the frequency of 
activated myelin specific T cells, as measured by CD25+CD69+ frequency, between genotypes or 
CNS compartments (Figure 2-3D). There were slightly more myelin-specific T cells in the brain 
vs the spinal cord of both WT and IFNgRKO recipients at preclinical time points (unpublished 
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data). Our laboratory has previously detected transferred T cells in the choroid plexus by 
immunofluorescent histology 4-5 days following adoptive transfer (2-3 days prior to standard 
disease onset) (unpublished data). This led us to hypothesize that encephalitogenic T cells 
initially infiltrate the CNS via the choroid plexus in both WT and IFNgRKO mice. IFNg 
production by donor T cells doesn’t occur until they are reactivated in the presence of cognate 
antigen presented by a CNS-resident antigen presenting cell. Therefore, we would not expect 
there to be a divergence in the evolution of cEAE and aEAE until after the until migration of T 
cells to the CNS. The choroid plexus has been identified as a key entry point for CD4 and CD8 T 
cells into the CNS during immune surveillance (3,4). A common portal of initial entry of T cells 
into the CNS at the inception of cEAE and aEAE would also explain the predominance of 
myelin-specific T cells in the brain compartments prior to disease onset, since the choroid plexus 
is situated within the ventricles of the brain. Investigators have identified the choroid plexus and 
BCSFB as key early entry points in other models of EAE(5,6).  
 
4b. a4 integrin is required for initial infiltration of Th1-polarized encephalitogenic T cells 
into the CNS prior to EAE onset 
 
While the pattern of infiltration of myelin-specific CD4 T cells does not differ in WT and 
IFNgRKO mice, this is not the case as disease progresses. At the peak of EAE we observed 
significant increases in transferred CD4 T cell accumulation in the SC of WT mice compared to 
IFNgRKO mice (Figure 2-2D, Figure 2-3B). We sought to identify a mechanism by which IFNg 
promoted encephalitogenic T cell accumulation in the spinal cord. It is known that interactions 
between a4b1 integrin on T cells and VCAM-1 on cerebrovascular endothelium are critical for T 
cell infiltration into the spinal cord during cEAE pathogenesis(7). In a toxoplasma model of 
neuroinflammation, IFNg signaling was critical for upregulating VCAM-1 expression in the CNS 
endothelium and mediating T cell infiltration to sites of infection(8). In our adoptive transfer 
model,  we found that VCAM-1 was only upregulated in the spinal cord and brainstem of WT 
but not IFNgRKO recipients over naïve controls (Figure 4-1A) while other markers of activated 
endothelium were elevated during both aEAE and cEAE.  
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 Figure 4-1:V-CAM-1 expression is not upregulated in the CNS of IFNgRKO mice  (A) Expression of VCAM-
1, P-selectin and E-selectin at the onset of cEAE or aEAE in whole CNS compartments normalized to endothelial 
marker (Tie2) and housekeeping gene (GAPDH). Shown has fold change over naïve control (dashed line). From two 
experiments WT: Naïve (n=3), cEAE (n=11) and IFNgRKO: naïve (n=3), aEAE n=14. (B) Expression of VCAM-1 
relative to GAPDH in the choroid plexus IFNgRKO: Naïve (n=7), onset aEAE (n=7) and WT: onset cEAE (n=3) 
Statistical analysis was performed using an unpaired students T-test. * p>0.05, ** p>0.01, ***p>0.001 
 
Blockade of a4 integrin is known to inhibit a4 VCAM-1 interactions that are required for 
the manifestation of cEAE. We speculated that aEAE in IFNgRKO mice would be independent 
of a4 integrin expression since VCAM-1 is not upregulated in CNS compartments during aEAE. 
Surprisingly, inhibition of a4 integrin signaling via administration of blocking antibodies 
following adoptive transfer completely inhibited aEAE as well as cEAE. T cell interactions with 
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endothelium in cEAE are thought to be a4b1 integrin mediated, however, a4 is also critical for 
a4b7-mediated migration of T cell subsets. Administration of anti-a4b7 integrin did not have 
any effect on cEAE incidence, however, aEAE incidence was partially inhibited (Table 4-1). 
Based on our findings with integrin blocking antibodies we hypothesized that cEAE required 
a4b1-VCAM-1 interactions while a4b7-MadCAM-1 interactions were more critical in aEAE 
due to the absence of VCAM-1 upregulation. However, antibody-mediated blockade of VCAM-
1 significantly decreased cEAE and aEAE incidence while anti-MadCAM-1 had no effect on 
cEAE or aEAE incidence (Table 4-2). Our findings indicate that a4-mediated interactions with 
VCAM-1 are critical for encephalitogenic Th1 T cell infiltration into the CNS. Other labs have 
shown that Th17, but not Th1-polarized, encephalitogenic a4 KO T cells can induce EAE 
following adoptive transfer(9). Th17 cells migrate through the choroid plexus via a CCR6-
dependent mechanism to induce EAE(6), indicating that a4-mediated pathways may be uniquely 
critical for EAE initiation in Th1 polarized cell subsets.   
Table 4-1: cEAE incidence in WT and aEAE incidence in IFNγRKO micetreated with α4 integrin blocking 
antibodies (0.1mg/dose) or a4b7 blocking antibodies (0.5mg/mL) every other day starting on d0 post-T cell 
transfer Each row represents an individual adoptive trasnfer experiment. Anti-α4 treatment blocked cEAE and 
aEAE incidence entirely. A Mantel-Haenszel chi-squared with continuity corrections was used to compare incidence 
of aEAE in control antibody vs anti-α4β7 treatment groups. Anti-α4β7 significantly inhibited aEAE compared to 
control antibody: Common odds ratio of 3.9653 with p<0.05.  
 
Previous work has shown that VCAM-1 is expressed on the choroid plexus in naïve mice 
and is upregulated following active immunization(5). However, the administration of CFA and 
# sick # recip # sick # recip
3 4 4 5
4 4 3 3
7 8 7 8
WT Conventional Incidence 
Rat IgG2a Anti- 4 7
88% 88%
Rat IgG2a 
# sick # recip # sick # recip
3 5 2 4
3 5 2 5
2 6 1 6
5 10 1 10
3 8 0 8
2 6 1 6
18 40 7 39
Anti- 4 7
45% 18%
IFNγRKO  Atypical Incidence
# sick # recip # sick # recip
5 5 0 5
4 5 0 5
9 10 0 10
Conventional Incidence in WT Recipients
Rat IgG Anti- 4
90% 0%
# sick # recip # sick # recip
4 5 0 6
5 5 0 5
9 10 0 11
Rat IgG Anti- 4
90% 0%
Atypical Incidence in IFN RKO Recipients 
α4β7 blockade
α4 blockade
*
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pertussis toxin alone can upregulate adhesion molecule expression (10) and its expression in 
adoptive transfer models has not been examined. Our transcript analysis of choroid plexus 
samples showed VCAM-1 is expressed by the choroid plexus in naïve mice and is not 
significantly upregulated at the onset of cEAE in WT mice or aEAE in IFNgRO mice (Figure 4-
1B). We believe that constitutive expression of VCAM-1 in the choroid plexus during 
homeostasis is sufficient to promote the initial infiltration of Th1-polarized encephalitogenic T 
cells via a4b1 or a4b7-dependent mechanisms. In order to directly assess the requirements of 
VCAM-1 expression on the choroid plexus epithelium during EAE conditional KO 
(Lymphotrophic papovavirus control region (LPV)-Cre(11)xVCAM-1fl/fl) may be useful. 
 
Table 4-2: cEAE incidence in WT and aEAE incidence in IFNγRKO mice treated with anti-VCAM-1 
(0.2mg/dose) or anti-MadCAM-1 (0.5mg.dose) blocking antibodies every other day starting on d0 post-T cell 
transfer Each row represents an individual adoptive transfer experiment. A Mantel-Haenszel chi-squared test with 
continuity corrections was used to compare incidence of EAE in control antibody vs experimental treatment. 
VCAM-1 significantly decreased cEAE incidence: common odds ratio of 16 with p<0.01, and aEAE incidence: 
common odds ratio of 10.8 with p<0.05. Anti-MadCAM-1 treatment did not significantly decrease EAE incidence in 
WT or IFNγRKO recipients.  
 
 
If VCAM-1 expression is required for the initial infiltration of Th1-polarized donor T 
cells via the choroid plexus during both cEAE and aEAE, we must alter our experimental 
# Sick # injected # Sick # injected
4 4 0 4
2 5 1 5
5 5 0 5
5 5 2 5
16 19 3 19
WT Conventional Incidence 
Rat IgG2b Anti-VCAM-1
84% 16%
# Sick # Recip # Sick # Recip
4 13 0 13
2 11 1 11
3 6 0 6
9 30 1 30
IFN RKO Atypical Incidence 
Rat IgG2b Anti-VCAM-1
30% 3%
# sick # recip # sick # recip
3 4 4 5
4 4 2 3
7 8 6 8
WT Conventional Incidence
Rat IgG2a Anti-MadCAM
75%88%
# sick # recip # sick # recip
3 5 2 4
3 5 2 4
6 10 4 8
Anti-MadCAM
50%
IFN RKO Atypical Incidence 
Rat IgG2a
60%
VCAM-1 blockade
MadCAM-1 blockade
***
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approach to assess the requirement for VCAM-1 upregulation specifically in the spinal cord 
endothelium in cEAE progression. We inhibited a4 integrin or VCAM-1 signaling by 
administering blocking antibodies starting the same day as the adoptive transfer itself. This likely 
blocked the initial infiltration of T cells via the choroid plexus. To interrogate the importance of 
VCAM-1 a4 integrin interactions following initial infiltration of T cells we could initiate anti-a4 
or anti-VCAM-1 treatments at the clinical onset of cEAE or aEAE. We anticipate that 
administration at this time point would block the progression of cEAE but not aEAE. 
Additionally, adoptive transfers into mice with genetic ablation of VCAM-1 expression restricted 
to endothelium (human von Willebrand factor (hVWF)-Cre(11)xVCAM-1fl/fl)) could be used to 
distinguish the requirement of VCAM-1 expression by the BBB endothelial cells vs choroid 
plexus epithelial cells.      
 
4c. IFNg promotes spinal cord inflammation by upregulating chemokines and adhesion 
molecules required for monocyte infiltration in the spinal cord 
 
We observed significant accumulation of monocytes in the spinal cord at the peak of cEAE but 
not IFNgRKO mice at the peak of aEAE (Figure2-2C). Previous studies by our lab and others 
identified Ly6Chi monocytes as critical drivers of cEAE(12,13). Examination of chemokine levels 
in the spinal cord and brainstem showed that WT mice had significantly higher levels of CCR2-
binding chemokines CCL2 and CCL5 as well as CXCR3-binding chemokines CXCL9 and 
CXCL10 (Figure 2-4). Both receptors are known to be expressed by monocytes(14,15). IFNg 
signaling can upregulate CXCL9 and CXCL10 levels in the CNS(16) and induce CCL2 
production by microglia and astrocytes(17,18). Other studies from our lab showed that 
deficiencies in CXCR3 or CXCL10 were dispensable for fulminant cEAE induced by Th1-
polarized myelin specific T cell adoptive transfers(19). In my own experiments, CCR2 KO 
recipients of Th1-polarized myelin specific T cell transfers had a lower incidence of cEAE 
compared to WT controls (Figure 2-5C). Some mice still had mild cEAE, indicating that CCR2-
dependent infiltration was critical for severe disease at peak but not induction of cEAE. Our 
findings are consistent with those of Fife et al. (20). Subsequent studies demonstrated suppressed 
monocyte and CNS homing in CCR2 deficient mice compared to WT controls following active 
immunization(13). While our findings contribute to the idea that CCR2 expression on monocytes 
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is critical for their infiltration in cEAE this has not been proven definitively. In order to assess 
the absolute requirement of CCR2 signaling in monocyte infiltration of the SC adoptive transfers 
into mixed BM chimeras containing both CCR2+/+ and CCR2-/- BM could be utilized to examine 
how deficiency in CCR2 affects monocyte recruitment to the SC during EAE.  
Few studies have focused on the potential role for VCAM-1 in monocyte CNS 
infiltration. Monocytes are known to utilize a4b1 integrin for infiltration into inflamed 
tissue(14). It is now well established that anti-a4 and anti-VCAM-1 treatment inhibits cEAE; the 
importance of a4 VCAM-1 interactions in monocyte infiltration into the SC during cEAE could 
be examined via adoptive transfers into mixed BM chimeras reconstituted with a4 integrin 
sufficient and deficient hematopoietic stem cells. We would predict that a4 integrin sufficient 
monocytes would have a competitive advantage over their a4 deficient counterparts for 
accumulation in the spinal cord.     
Taken together our data identify IFNg as a critical regulator of multiple factors that 
promote monocyte and myelin-specific T cell infiltration into the SC and cEAE pathogenesis. 
The direct cellular target(s) of IFNg are what remains to be identified. Conditional KO of the 
IFNgR would allow us to target individual CNS resident cell types astrocytes (GFAP-Cre), 
endothelial cells of the BBB (VWF-cre) and choroid plexus epithelium (LPV-Cre), to determine 
where responses to IFNg are critical for promoting spinal cord inflammation in cEAE.  
 
4d. CXCR2 dependent neutrophil accumulation in the brainstem is critical for aEAE 
pathogenesis  
 
In the absence of IFNgR signaling we observed a distinct pattern of CNS infiltration at the peak 
of EAE characterized by neutrophil accumulation in the brainstem (Figure 2-2a). This correlated 
with higher levels of CXCL2 in the brainstem at the onset of aEAE when compared to cEAE 
(Figure 2-4). Blockade of CXCR2 specifically inhibited aEAE pathogenesis and had no effect on 
cEAE in our model. In parallel to our own studies, Simmons et al. showed that CXCR2 
antagonists block clinical disease in an IL-17-dependent model of aEAE(21). Additionally, in a 
LysM-Cre SOC3fl/fl mouse model of atypical EAE, administration of a Ly6G-blocking antibody 
decreased the incidence and severity of aEAE(22). Hence infiltration of the brain by neutrophils 
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in a CXCR2-dependent manner is critical for multiple models of aEAE. We sought to identify 
the specific factors that promote CXCL2 production in the BS during aEAE and mechanisms by 
which IFNg could suppress CXCL2 production and hence neutrophil accumulation in the 
brainstem and aEAE.  
 
4e. CXCL1 and CXCL2 are produced by distinct cell subsets and are differentially 
regulated by IFNg during EAE 
 
Next we sought to identify the cellular sources of CXCR2-binding in adoptive transfer recipients. 
Immunohistology at the onset of EAE identified CNS-resident cell types such as choroid plexus 
epithelial cells and astrocytes as CXCL1+, while CD45+CD11b+ cell subsets were CXCL2+ 
(Figure 3-5). CXCL2 transcript and protein levels were elevated in CD45+CD11b+ subsets within 
the brainstem parenchyma (Figure 3-4). Models of neutrophil recruitment to sites of 
inflammation differ on the requirement for CXCL1 versus CXCL2 signaling. Blockade of 
CXCL1 or CXCL2 inhibited neutrophil extravasation into peritoneal fluid following LPS 
injection(23), while neutrophil infiltration into tumor draining lymph nodes only requires 
CXCL2(24). The differential pattern of CXCL1 and CXCL2 expression in aEAE may signify 
distinct roles for CXCL1 and CXCL2 in promoting neutrophil migration out of circulation and 
migration into CNS parenchyma.  
 
4f. IFNg suppresses monocyte and microglial production of neutrophil chemoattractant 
CXCL2 
 
CXCL2 is elevated in the brainstem at the onset of aEAE compared to cEAE. Protein and mRNA 
analysis of brainstem cell subsets at the onset of aEAE identified myeloid cells as predominant 
producers of CXCL2. Further examination of purified microglial and monocyte populations from 
WT and IFNgRKO recipients at the onset of EAE showed that CXCL2 transcript levels were 
elevated in IFNgRKO microglia and monoctyes (Figure 3-4B). We also found that CXCL2 
expression was directly attenuated by IFNg signaling specifically in the CNS during EAE. 
IFNgRKO monocyte/macrophage populations isolated from the CNS at the onset of EAE in 
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WT/IFNgRKO mixed BM chimeric mice had significantly higher levels of CXCL2 transcript 
compared to WT counterparts (Figure 3-4). In contrast, there was no difference in CXCL2 
expression comparing WT and IFNgRKO cells derived from the BM in the mixed BM chimeras. 
In other model systems, stimulation of TLR4 on monocytes, macrophages and microglia induces 
CXCL2 expression (25,26). In vitro experiments showed that IFNg inhibits CXCL2 protein 
production by BM monocytes following LPS stimulation (Figure 3-6C). Taken together, our data 
shows that IFNg directly regulates CXCL2 production by monocytes and microglia, however the 
factors that induce CXCL2 production in each cell type during aEAE is not known. 
There are multiple potential stimuli of CXCL2 production from resident microglia and 
macrophages at the onset of aEAE. Infiltrating T cells produce TNFa and GM-CSF following 
reactivation. This can induce IL-6 and IL-1b production from CNS support cells and infiltrating 
immune cells. All of these factors are present in the brainstem at the onset of aEAE (Data not 
shown) and can contribute to microglial/macrophage activation and induce neutrophil 
chemoattractant production(27) (28). Co-cultures of CNS microglia/macrophages with MOG-
specific T cells and MOG peptide, or in the presence of candidate pro-inflammatory factors can 
be used to identify whether these stimuli are sufficient to induce CXCL2 production. 
Additionally, we have identified TLR activation as a potential mechanism for CXCL2 
production by monocytes, however the specific stimulus that induces its production in aEAE is 
not known. Following via TLR engagement by danger associated molecular patterns released 
following CNS damage microglia and CNS-resident macrophages can be activated (29). While 
we have shown stimulation of TLR4 promotes CXCL2 production by bone marrow monocytes 
in vitro, we haven’t examined potential danger signals that may be present in the brainstem 
during aEAE and their ability to stimulate CXCL2 by microglial and macrophage populations 
isolated from the CNS. Analysis of danger signals present in the brainstem at the onset of aEAE 
particularly those that bind TLR4, such as High mobility group box-1 (HMGB-1) and Heat 
Shock Protein (HSP-60 and 70), and subsequent stimulation of microglial, macrophage and 
monocyte cultures may identify a particular stimulus of CXCL2 production in response to early 
CNS damage in aEAE. Myd88-/- and TLR2-/- hosts are resistant to adoptive transfer cEAE 
however TLR4-/- hosts are not (30,31) indicating that multiple pathways of DAMP responses 
may be critical for induction of EAE in different model systems. Inquiry into the TLR and 
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responses critical for aEAE may allow us to identify distinct DAMP signals that promote cEAE 
and aEAE.  
 
4g. IFNg dampens response to and production of CXCL2 by neutrophils in the CNS 
 
We believe the initial production of CXCL2 by microglia and early infiltrating myeloid cells is 
critical for the initiation of aEAE, however, subsequent activation of a CXCL2 response and 
production loop in neutrophils is critical for aEAE progression. At the onset of EAE we found 
that CXCL2 transcript levels were highest in neutrophil populations sorted out of the CNS 
(Figure 3-4A). Flow cytometric analysis of intracellular CXCL2 identified neutrophils as a major 
source of CXCL2 in the brainstem during aEAE (Figure 3-3C). CXCL2 transcript expression in 
neutrophils isolated from the brainstem correlated with scores at aEAE onset (Figure 3-3B). This 
increased CXCL2 transcript production correlates with increased neutrophil accumulation in the 
brainstem during aEAE (Figure 4-2). This observation led us to hypothesize that neutrophil 
accumulation drives increased CXCL2 production in an autocrine/paracrine loop of CXCL2 
response by neutrophils stimulating CXCL2 production. We found that CXCL2 production by 
neutrophils was upregulated by incubation with either CXCL2 or CXCL1 alone. In the presence 
of IFNg, CXCR2-dependent upregulation of CXCL2 transcript was significantly inhibited, 
however G-CSF-dependent upregulation of CXCL2 was not. Indicating that IFNg may be 
directly affecting CXCL2 production in response to CXCR2 binding chemokines (Figure 3-6A 
and B). Analysis of neutrophils isolated from mixed WT/IFNgRKO BM chimeras at the onset of 
EAE showed that IFNg directly inhibits neutrophil production of CXCR2 (Figure 3-2) and 
CXCL2 (Figure 3-4D) in the CNS but not in the periphery.  
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Figure 4-2: Microglia (CD45loCD11b+Ly6G-), monocyte (CD45hiCD11b+Ly6G-), and neutrophil 
(CD45+CD11b+Ly6G+) cell numbers from the spinal cord and brainstem of mice at the onset of EAE in WT 
and IFNgRKO mice. cEAE (n=10), mild onset of aEAE (score=1) (n=8) and severe onset of aEAE (score≥2) (n=7). 
Statistical analysis was performed using an unpaired students T-test. * p>0.05, ** p>0.01, ***p>0.001 
 
CXCR2 dependent production of CXCL2 by neutrophils has been demonstrated in other models 
of inflammation(32), but the role of IFNg in regulating that pathway has not been studied. Our 
data demonstrate that IFNg signaling in neutrophils directly suppresses CXCR2-dependent 
CXCL2 production, however the exact pathway that IFNg is acting on is unknown. In vivo 
evidence showed that IFNg can directly downregulate CXCR2 expression. In vitro evidence 
points to an additional rapid mechanism of IFNg-mediated suppression of CXCL2 signaling, 
since addition of IFNg to cultures of neutrophils with CXCL2 is sufficient to suppress 
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upregulation of CXCL2 (Figure 3-6A and B) after a 1 hour incubation period in response to 
CXCR2 stimulation without affecting CXCR2 transcript levels (data not shown) 
 There are multiple pathways downstream of G-protein coupled receptor (GPCR) 
signaling that IFNg could be acting on to suppress CXCR2 signaling. One rapid pathway of 
GPCR downregulation is heterologous desensitization, where activation of secondary 
messengers downstream of one receptor can lead to the phosphorylation, and subsequent 
inactivation, of another. Since this process only requires second messenger interactions the effect 
can often be seen within 30 minutes(33). One major heterologous desensitization pathway works 
through cAMP-PKA mediated phosphorylation of GPCRs(34). IFNg can induce cAMP PKA 
(35) and could inhibit CXCR2-meditated upregulation of CXCL2 transcript through 
heterologous desensitization in addition to direct suppression of CXCR2 transcript expression.  
If IFNg doesn’t suppress CXCL2 mRNA induction via heterologous desensitization, 
further elucidation of the exact pathway by which CXCR2 signaling induces CXCL2 expression 
may help to identify the target. Using the inhibitors listed in Figure 4-3 we can interrogate which 
pathways downstream of CXCR2 ligation are critical for CXCL2 production. If we are able to 
identify a specific pathway required for CXCL2 production, we can then identify potential 
mechanisms by which IFNg signaling could inhibit CXCR2 dependent second messenger signals 
of CXCL2 production.  
Figure 4-3: CXCR2 signaling pathway with inhibitors of each step in the pathway indicated with red block 
arrows(36). 
 
IFNg may also regulate the access of CXCR2-dependent transcription factors to CXCL2 
promoter regions via epigenetic modifications. A recent study demonstrated epigenetic 
suppression of LPS-induced production of IL-6, IL-1b and CXCL1 in BM macrophages 
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Fig. 4. Signaling through CXCR2 is required for HpHSP60-mediated angiogenesis. (A) Potential signaling pathways for HpHSP60-induced angiogenesis. IL-8 and GRO could
engage with CXCR2 and turn on downstream molecules including MAP kinase [23,38], PI3 kinase [23,39], and PLCb2 [26] to promote angiogenesis. Inhibitors to these specific
signal pathways are used to investigating underlying molecular mechanisms. (B) HUVECs were treated with or without (control) 10 lg/ml HpHSP60 for 6 h after pre-
treatment with SB225002 (50 nM), BAPTA (3 lM), PD98059 (5 lM), or wortmannin (10 nM) for 1 h. Tube branch points were then scored and are represented as % tube
branch points where un-stimulated cells were equal to 100%. The data are expressed as the mean ± SEM, *p < 0.01 compared to HpHSP60 treatment alone. All experiments
were performed in triplicate.
C.-S. Lin et al. / Biochemical and Biophysical Research Communications 397 (2010) 283–289 287
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mediated by IFNg STAT-1 dependent pathways(37). Further examination of transcription factor 
binding and methylation states of CXCL2 and CXCR2 promoter regions in WT and IFNgRKO 
neutrophils may identify novel epigenic mechanism of IFNg mediated regulation of the 
neutrophil CXCL2 autocrine/paracrine positive feedback loop.  
Taking all of our data together on CXCR2-binding chemokines in aEAE, we propose that 
CXCL1 production by the choroid plexus in response to master inflammatory cytokines such as 
IL-6 and TNF-a, released following encephalitogenic T cell activation in the CNS promotes the 
initial recruitment of neutrophils through the BCSFB. However, in the absence of subsequent 
CXCL2 responses that are suppressed by IFNg, parenchymal infiltration of the brainstem by 
neutrophils and subsequent aEAE pathogenesis are inhibited. Antibody blockade of CXCL1 or 
CXCL2 individually in our Th1-polarized adoptive transfer into IFNgRKO mice would elucidate 
the absolute requirement of CXCL1 and CXCL2 for aEAE. If both chemokines are important for 
aEAE pathogenesis, subsequent experiments focusing on conditional deletions of CXCL1 in 
different CNS resident cell subsets and CXCL2 in different myeloid cell subsets can help us 
identify what cells are critical sources of these chemokines during aEAE.   
 
  
4h. Examining mechanisms of neutrophil damage to CNS parenchyma   
 
 The CXCL2-CXCR2 axis of neutrophil recruitment is critical for aEAE pathogenesis but 
the mechanisms by which neutrophil infiltration causes damage to the brainstem are unknown. 
Activated neutrophils produce matrix metalloproteases (MMPs) which can promote 
inflammation and digest extracellular matrix proteins to promote breakdown the tight junctional 
barriers in the CNS(38). In human neutrophils, CXCR2 engagement triggered MMP-9 release 
from tertiary granules(39). MMP-9, induced downstream of CXCR2 signaling, promotes 
neutrophil migration into uroepithelium in a bacterial infection model(40). MMP-2 and MMP-9 
have been shown to mediate b-dystroglycan digestion around astrocyte endfeet and subsequent 
immune cell infiltration into the spinal cord in EAE(41), but their role in neutrophil migration 
into CNS parenchyma has not been studied. Using adoptive transfers of encephalitogenic 
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IFNgKO CD4 T cells into MMP-9 and/or MMP2 KO mice we can examine whether MMPs play 
a role in aEAE.  
 
4i.  Examining the heterogeneity of CNS autoimmunity through analysis and 
characterization of immune cell recruitment profiles  
 This project characterizes two distinct pathways of immune cell infiltration into the CNS 
which are modulated through distinct chemokine pathways and which recruit variable cell types 
to the CNS. Direct correlation between lesion localization in rodent models and MS patients is 
unlikely due to significant differences in CNS physiology, however animal models can still be 
used to study the diverse pathways by which immune cells infiltrate the CNS. Current MS 
therapeutics target a restricted panel of immune related molecules with variable results for 
individual patients. Most of these therapies have been developed with the assumption that the 
vast majority of MS pathophysiology is driven by infiltration of T cell, B cell and 
monocyte/macrophage subsets, however expansion in our understanding of the complexity of 
MS progression has generated new potential targets for disease therapy.  
The role of neutrophils in CNS autoimmunity has gained a lot of traction recently, 
however therapies targeting them are not widely utilized. In addition to clinical studies showing 
the administration of G-CSF induced relapses in MS patients(42-45), elevated levels of 
neutrophil chemoattractants have been identified in progressive MS patients(46) as well as those 
with opticospinal form of MS(47). Neutrophils are also predominant in lesions of NMO patients 
who also have a predominantly spinal cord and optic-nerve focused disease(48). The increased 
presence of neutrophils NMO and progressive forms of MS may account for their non-
responsiveness to a4 integrin-blocking therapies. The effectiveness of a4 integrin in opticospinal 
forms of MS has not been examined. While some studies have identified correlates between 
lesion distribution and cytokine/chemokine levels in patient serum and CSF(47), the detailed 
analysis of these factors and immune cell subset characterization in MS patients has not been 
well described. The heterogeneity of migratory pathways utilized in immune cell infiltration into 
the CNS has been well described in our model and throughout the literature, however detailed 
analysis of patient blood and CSF for cytokine, chemokine and immune cell subset 
characterization has not yet been performed. To increase the efficiency of disease modifying 
therapy selection and better understand how these drugs are working it is imperative that studies 
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are undertaken to develop profiles of patient immune responses and identify markers of 
responders and non-responders to specific therapies. This work could inform diagnosis and 
treatment, and also identify profiles of disease that do not respond to current therapies which 
informs potential cell and molecular targets to pursue in the future.  
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